5-Aminohexahydro-6,7,8-trihydroxy-3H-oxazolo[3,4-A]pyridin-3-one derivatives as TLR4 modulators for the treatment of immune diseases

Novel glycolipid mimetics with a polysubstituted 2-oxa-3-oxoindolizidin-5-yl radical via a pseudoamide group address the limitations of current anti-inflammatory drugs by providing targeted, metabolically stable TLR4 modulation for effective inflammatory disease treatment.

JP2024543018AInactive Publication Date: 2024-11-19CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024525642
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-29
Filing Date
2022-10-26
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for inflammatory diseases lack target specificity and are hindered by side effects, with existing anti-inflammatory drugs facing challenges in clinical application due to their complex chemical structures and enzymatic instability, limiting their effectiveness and safety.

Method used

Development of novel glycolipid mimetics with a polysubstituted 2-oxa-3-oxoindolizidin-5-yl radical attached via a pseudoamide group, ensuring metabolic stability and stereoselectivity, which act as TLR4 antagonists or agonists to modulate immune responses and provide anti-inflammatory effects.

Benefits of technology

The glycolipid mimetics effectively suppress inflammatory cytokines and enhance anti-inflammatory responses, offering a targeted and stable solution for treating inflammatory diseases with reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543018000001_ABST
    Figure 2024543018000001_ABST
Patent Text Reader

Abstract

The present invention relates to glycolipid-mimetic derivatives of formula I, 1 is defined herein), or pharmaceutical compositions thereof, and their use for the treatment and / or prevention of immune diseases acting as an antagonist or agonist of TLR4. [Formula 1] JPEG2024543018000041.jpg30169
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] The present invention relates to a compound of formula I, 1 The present invention relates to a glycolipid-mimetic derivative of TLR4 (as defined herein), or a pharmaceutical composition thereof, and its use for the treatment and / or prevention of immune diseases, acting as an antagonist or agonist of TLR4.

[0002] [Background technology] Inflammation is the physiological response of the immune system to injury or infection. This process activates signaling pathways aimed at healing and repairing damaged tissues and defending against infectious agents such as viruses and bacteria. However, if unresolved or inappropriately activated, inflammation can contribute to pathogenesis. Chronic inflammation is the underlying cause of a wide range of diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD; including digestive disorders such as Crohn's disease and ulcerative colitis), chronic obstructive pulmonary disease (COPD), asthma, psoriasis, and idiopathic pulmonary fibrosis (IPF), among others. On the other hand, viral and bacterial infections, or hostile agents such as toxins and chemicals, can trigger uncontrolled acute inflammatory responses and injury, which are often seen in patients with underlying diseases such as COPD and asthma. A recent example of viral inflammation leading to acute lung injury and acute respiratory distress syndrome is SARS-CoV-2 infection, which is associated with a cytokine storm characterized by high levels of IL-6, IL-12, IL-1β, and tumor necrosis factor (TNF), as well as a deficiency in type I interferon activity. Although a range of biologics and chemotherapy are effective in treating various inflammatory diseases, the majority of patients do not respond to current therapies, highlighting the need for new therapies. Lack of target specificity and side effects are current issues that hinder the clinical application of small molecule anti-inflammatory drugs. The discovery of novel target-specific compounds for the treatment of these diseases is a major challenge that could have significant scientific, commercial, and societal impacts. For a general view on inflammation, including mechanisms of inflammation, inflammation-related pathologies, current anti-inflammatory therapies, and remaining challenges, see: Innate Immunity 2021, 27, 275-284;Pharmaceutics 2021, 13, 64;Nature 2008, 454, 24.

[0003] Carbohydrates play a key role in regulating immune system function and immune responses, and various natural carbohydrate-based immunomodulators have been clinically evaluated for their application as anti-inflammatory drugs. However, immune-active carbohydrates from natural products are usually difficult to obtain in sufficient quantities, purity, and homogeneity. Organic synthetic chemistry, including total and semi-synthetic methods, offers a more attractive approach to molecularly defined improved forms of carbohydrate-containing anti-inflammatory drugs, allowing the modification of the corresponding natural product structure with a high level of chemical control. In that sense, glycolipid derivatives acting as antagonists of Toll-like receptor 4 (TLR4) are one of the attractive options. For selected reviews on carbohydrate derivatives, in particular glycolipids, as immunomodulators see: Org. Biomol. Chem., 2011, 9, 3080-3104; Molecules 2013, 18, 15662-15688; Clin. Transl. Immunol. 2016, 5, e69; Chem. Eur. J. 2017, 23, 1728-1742; Nat. Rev. Chem. 2021, 5, 197-216.

[0004] TLR4 belongs to the pattern recognition receptor family and plays a key role in the human defense mechanism, responding to invading pathogens with high selectivity and sensitivity. TLR4 is sensitive to pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS) and lipooligosaccharide (LOS). In addition, TLR4 also recognizes PAMPs from fungi, viruses, and mycoplasma. In addition to PAMPs, TLR4 is also activated by certain endogenous ligands produced by tissue injury and / or inflammation. This receptor-ligand interaction initiates an intracellular signaling cascade that leads to subsequent proinflammatory responses. Given the involvement of TLR4 in various pathologies involving inflammation, compounds that antagonize TLR4 by acting on the TLR4-dependent signaling cascade may be candidates for anti-inflammatory drugs. For selected reviews on TLR4 and TLR4 antagonists as anti-inflammatory drugs, see: Molecules 2020, 25, 627; Front. Immunol. 2020, 11, 1210; Nat. Drug Discov. 2021, 20, 39. Interestingly, anti-inflammatory TLR4 antagonists can also be used to formulate vaccine adjuvants. As an example, monophosphoryl lipid A (MPL®), a vaccine adjuvant produced from Salmonella enterica endotoxin with wide clinical and market acceptance, has been shown to contain two structural variants that function as competitive antagonists of human TLR4 (see Front. Immunol. 2020, 11, 577823). The partial agonist profile required for adjuvant action can be reproduced and engineered by spiking synthetic agonists with synthetic antagonists to achieve a wide dose range that can suppress TLR4 stimulation below the desired threshold. Furthermore, it should be considered that compounds acting on the TLR4 signaling pathway may ultimately express antagonist or agonist activity in a context-dependent manner, allowing, for example, the treatment of inflammatory pathologies and the promotion of immune responses to a given antigen, thereby acting as adjuvants.

[0005] Several glycolipids targeting the TLR4 pathway have already reached clinical trials. A representative example of a TLR4 antagonist with anti-inflammatory properties is the underacylated lipid A analogue eritoran (E5564). Eritoran was evaluated as a treatment for sepsis. Unfortunately, however, eritoran failed to achieve the targeted endpoints in phase 3 trials. Moreover, the complexity of the chemical structure, especially the presence of two labile anionic phosphate groups in the aminodisaccharide core of eritoran and other lipid A analogues, makes the synthesis rather laborious and represents a significant hurdle for optimization strategies. For relevant literature in this regard, see: J.Am.Chem.Soc.2019,141,947-9478;Med.Res.Rev.2019,39,1053-1090;Future Med.Chem.2018,10,461-476.

[0006] Neutral trivalent α-D-mannopyranoside derivatives with long acyl lipid chains have also been found to act as TLR4 antagonists, as reported in ACS Chem.Biol. 2015, 10, 2697-2705. Due to the enzymatic instability of the O-glycosidic bond, these compounds are unstable in biological media and have not progressed to clinical trials.

[0007] More recently, metabolically stable glycolipid mimetics with monosaccharide-like polysubstituted 2-oxa-3-oxoindolizidin-5-yl radical glycocon moieties linked via a sulfur (S) atom to the lipid aglycone have been reported to elicit anti-inflammatory responses in immune system cells, such as microglia and dendritic cells, exposed to LPS, as well as in mouse models of acute inflammation. The glycocon moieties contained in these compounds are so-called sp 2 -iminosugar glycomimetic family, and the conjugation with the corresponding lipid aglycone is sp 2-iminoglycosylglycolipids. Mechanistic studies have confirmed that this type of compound acts on the TLR4 inflammatory cascade, modulating the phosphorylation state of mitogen-activated protein kinases (MAPKs) such as JNK and p38α, and reducing the levels of inflammatory cytokines and reactive oxygen species (ROS). At the same time, this type of compound enhances the expression of anti-inflammatory markers. There is a narrow range of sulfur functional groups that exhibit the desired activity, namely sulfones and sulfoxides, the latter of which are (S S ) and (S R The main limitation is the fact that these are obtained as a mixture of diastereomers of S-linked glycolipid mimetics, which must be separated. For related literature on this type of S-linked glycolipid mimetics as anti-inflammatory agents, see: Eur. J. Med. Chem. 2019, 169, 111-120; Food Chem. Toxicol. 2018, 111, 454-466; Biochim. Biophys. Acta 2016, 1862, 1663-1674.

[0008] sp 2 Substitution of the pseudo-anomeric sulfur with an amine (NH) group in N-iminoglycosylglycolipid mimetics has been explored, but as reported in Eur. J. Med. Chem. 2019, 182, 11160, only N-glycosylglycolipid mimetics bearing polyfluoroalkyl segments were found to exhibit anti-inflammatory activity. Furthermore, due to the basic properties of the amine group, these compounds are pH sensitive. Most concerning, the amine-linked sp 2 -iminosugar conjugates have been reported to behave as inhibitors of various glycosidases, which may result in undesirable side effects. For relevant literature in this regard, see: Chem. Commun., 2010, 46, 5328-5330; Carbohydr. Res. 2016, 429, 113-122. Thus, the search for metabolically stable glycolipid mimetics with specific TLR4 antagonistic activity, accessible by efficient synthetic approaches, to be used as anti-inflammatory drugs is ongoing.

[0009] Pseudoamide derivatives, i.e. derivatives incorporating achiral functional groups containing a NX(=Y)-segment (where X is a carbon (C), sulfur (S) or phosphorus atom (P) bearing at least one double bond and Y is oxygen (O), sulfur, selenium (Se) or nitrogen (N)), are characterized by high chemical and enzymatic stability and allow efficient synthesis. In earlier patent literature, namely patent ES 2 370 852 B1, it was reported that sp 2 A limited number of examples of derivatives have been reported in which the -imino sugar glycone moiety is linked to the aglycone moiety via a pseudoamide group, in particular a urea group, a thiourea group, or a guanidine group. The compounds are said to act as inhibitors of α-glucosidase and are useful in the treatment of diseases mediated by α-glucosidase. Selected examples include cancer, viral infections, tuberculosis, diabetes, and glycosphingolipid storage disorders. However, the patent documents do not claim the use of the compounds as anti-inflammatory agents, nor provide evidence of the anti-inflammatory activity of the compounds. Nor does the information contained in the cited patent documents lead one to infer that the compounds exhibit anti-inflammatory properties and can be used as anti-inflammatory agents for the treatment of inflammation-related diseases.

[0010] Further patent literature (e.g., WO2013 / 054070Al) and non-patent literature (e.g., ACS Omega 2020,5,16263-16271) reports glycomimetics of the iminosugar type that have anti-inflammatory activity in certain contexts. None of these glycomimetics contain a 2-oxa-3-oxoindolizidine core or incorporate a lipid moiety. As with the above-mentioned technologies, their biological activity is related to their ability to inhibit certain glycosidases. No evidence of a mechanism of action suggesting TLR4 antagonism or agonism has been presented.

[0011] In view of the above, it would be useful to identify further glycolipid-like agents that can specifically induce anti-inflammatory responses or modulate immune responses by antagonizing or agonizing the TLR4 receptor. Of particular interest is the development of new strategies to make such compounds available with high efficiency, ensuring (a) perfect stereoselectivity in generating the glycosidic bond, (b) metabolic stability, and (c) compatibility with molecular diversity-oriented strategies, allowing systematic modification of the structure to optimize the immunomodulatory profile towards an anti-inflammatory response.

[0012] Summary of the Invention The present invention discloses novel glycolipid mimetics that are metabolically stable and can be selectively modified to optimize the immunomodulatory profile in terms of promoting anti-inflammatory or adjuvant responses. The present invention also discloses novel glycolipid mimetics that can express anti-inflammatory and adjuvant activities in a context-dependent manner. The present invention also provides a process for obtaining said glycolipid mimetics with complete stereoselectivity. Furthermore, the present invention provides pharmaceutical products, such as anti-inflammatory agents or vaccines, that contain the glycolipid mimetics.

[0013] According to the present invention, compounds in which (i) the sugar-like glycone moiety, which is part of a glycolipid mimic, is a polysubstituted 2-oxa-3-oxoindolizidin-5-yl radical, (ii) this radical is attached to the lipid aglycone moiety via an achiral pseudo-amide functional group, and (iii) said glycone radical is directly attached to the nitrogen atom of the pseudo-amide group selectively induce the production of cytokines associated with anti-inflammatory responses. The present invention discloses a process for preparing the compounds according to the present invention, which have complete α-anomeric stereoselectivity and are not degraded by α-glycosidases that hydrolyze glycosidic bonds in natural or synthetic α-glycolipids, ensuring higher metabolic stability. Furthermore, the present invention discloses compounds according to the present invention that are useful for modulating the immune system towards anti-inflammatory cytokine producing cells. Thus, the compounds according to the present invention can be used for the treatment and / or prevention of inflammation-related conditions.

[0014] A first aspect of the present invention relates to a compound of formula I:

[0015] [ka]

[0016] Here, R 1 are each independently -H, -CH2Ph(Bn), -COPh(Bz), -CO-C1-C 12 Alkyl, C1-C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2 has been replaced by; R 2 -OH, -N(R 3 )2, -N3, C1-C4 alkyl, or halogen; R 3 are each independently H, or C1-C4 alkyl; X is -C(=S)-OY, -C(=Se)-NHY, -SO2-NYY', -SO2-OY, or -P(=O)(OY); Y is one or more groups R 4 -C1-C optionally substituted with 25 is alkyl; Y' is H or one or more groups R 4 Optionally substituted -C1-C 25 is alkyl; R 4 -OH, OBn, C1-C 12 Alkyl, -O-C1-C 12 Alkyl, -S-C1-C 12 Alkyl, -N(R 3 )2, -N3, -C(=O)-C1-C 12 alkyl, or Cy1; and Cy1 is a 5-14 membered ring which may be saturated, partially unsaturated, or aromatic and optionally contains a total of 1-4 identical or different heteroatoms selected from N, O, S, or P; Cy1 may be optionally fused to a 5- or 6-membered carbocyclic or heterocyclic ring which may be saturated, partially unsaturated, or aromatic; Cy1 is optionally substituted by one or more groups selected from phenyl, halogen, C1-C4 alkyl, halo-C1-C4 alkyl, -O-C1-C4 alkyl, -OCOO-C1-C4 alkyl, -CO-C1-C4 alkyl, S-C1-C4 alkyl, or N3-C1-C4 alkyl.

[0017] In another embodiment, the present invention provides a method for the preparation of 1 each independently selected from -H, -Bn, -Bz, -CO-C1-C4 alkyl, and -C1-C4 alkyl; R 1 each independently optionally represents one or more groups R 2 With respect to the compounds of formula I as defined above, preferably R 1 are each independently selected from -H, -Bn, -Bz, -CO-CH3(Ac), and -C1-C4 alkyl; R 1 each independently optionally represents one or more groups R 2 and more preferably, each R 1 is independently selected from -H, Bn, Bz, Ac, and -C1-C4 alkyl; more preferably, R 1 are each independently selected from -H and Ac.

[0018] In another embodiment, the present invention relates to a compound of formula I as defined above, wherein X is selected from -C(=S)-OY, -C(=Se)-NHY, -SO2-NYY', -SO2-OY, or -P(=O)(OY); preferably, X is selected from -C(=Se)-NYY', -SO2-NYY', -SO2-OY, or -P(=O)(OY); more preferably, X is selected from -C(=Se)-NHY', -SO2-NYY', or -SO2-OY, even more preferably, X is -C(=Se)-NHY', or -SO2-NYY'.

[0019] In another embodiment, the present invention provides a compound in which Y is optionally selected from one or more groups R 4 -C2-C substituted with 18 With respect to compounds of formula I as defined above, wherein Y is -C-C 18 It is an alkyl.

[0020] In another embodiment, the present invention provides a compound in which Y′ is H or, optionally, one or more groups R 4 substituted with -C2-C 18 For compounds of formula I as defined above which are alkyl, preferably Y' is H.

[0021] In another embodiment, the present invention relates to a compound of formula I as defined above, wherein X is selected from -C(=S)-OY, -C(=Se)-NHY, -SO2-NYY', -SO2-OY, or -P(=O)(OY); preferably, X is selected from -C(=Se)-NYY', -SO2-NYY', -SO2-OY, or -P(=O)(OY); more preferably, X is selected from -C(=Se)-NHY', -SO2-NYY', or -SO2-OY, even more preferably, X is -C(=Se)-NHY', or -SO2-NYY'; Y is optionally one or more groups R 4 substituted by -C2-C 18 alkyl, preferably Y is -C-C 18 is alkyl; and Y' is optionally H or one or more groups R 4 substituted by -C2-C 18 Preferably Y' is H and is alkyl.

[0022] In another embodiment, the compound of formula I as defined above is selected from:

[0023] [ka] JPEG2024543018000004.jpg252169JPEG2024543018000005.jpg229169JPEG2024543018000006.jpg181169

[0024] In some embodiments, any stereochemical pattern of the polysubstituted 2-oxa-3-oxoindolizidin-5-yl moiety (A) and any substituent R of formula I may be used. 1 and X may be independently combined, i.e., the individual substituents may be selected from multiple compounds as if each specific combination was explicitly recited.

[0025] As used herein, the singular forms "a," "and," and "the" include plural references unless the context clearly dictates otherwise. For example, "a compound" refers to one or more of such compounds known to those of skill in the art.

[0026] Throughout this application, the terms "compound" or "compounds" refer to the compounds discussed herein and are intended to include precursors and derivatives of the compounds, including acyl-protected derivatives, as well as pharma- ceutically acceptable salts of the compounds, precursors and derivatives.

[0027] The compound of formula I of the present invention can act as an antagonist or antagonist of TLR4 receptor in immune system cells.In yet another embodiment, the compound of formula I of the present invention can induce anti-inflammatory response.In another embodiment, the compound of formula I of the present invention can counteract the inflammatory response caused by a third agent.In an exemplary embodiment, the compound of formula I of the present invention can act as an antagonist or agonist of TLR4 receptor in immune system cells in vitro.In another embodiment, the compound of formula I of the present invention can act as an antagonist or agonist of TLR4 receptor in immune system cells in vivo.

[0028] The present invention also includes prodrugs of the compounds, pharmaceutical compositions comprising the compounds and a pharma- ceutically acceptable carrier, and pharmaceutical compositions comprising prodrugs of the compounds and a pharma- ceutically acceptable carrier.

[0029] The compounds of formula I of the present invention may contain one or more asymmetric centers and therefore may exist as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Depending on the nature of the various substituents on the molecule, additional asymmetric centers may exist. Each such asymmetric center independently produces two optical isomers, and all possible optical isomers and diastereomers in mixtures and pure or partially purified compounds are intended to be included within the scope of the present invention. Any formula, structure or name of a compound described herein that does not specify a specific stereochemistry is intended to include any existing isomers as described above, and mixtures thereof in any ratio. When a stereochemistry is specified, the present invention is meant to include that specific isomer in pure form or as part of a mixture with other isomers in any ratio.

[0030] Thus, the compounds of formula I of the present invention may contain chiral centers or double bonds. When they contain chiral centers, they may have the (R) or (S) configuration. When they contain double bonds, they may have the (Z) or (E) configuration.

[0031] In accordance with the present invention, the term "pseudo-amide group" refers to a nitrogen-containing functional group that includes a N-X(=Y)-segment, where X is a carbon (C), sulfur (S), or phosphorus (P) atom having at least one double bond, and Y is oxygen (O), sulfur (S), selenium (Se), or nitrogen (N).

[0032] The term “C1-C4, C1-C 12 , C1-C 25 , and C2-C 18 "Alkyl" as a group or part of a group means a straight or branched alkyl chain containing 1 to 4, 1 to 12, 1 to 25, or 2 to 18 carbon atoms, respectively, and may contain unsaturation. "Unsaturation" may be double or triple bonds.

[0033] "Halogen" means fluoro, chloro, bromo, or iodo.

[0034] The term Cy1 refers to a 5- to 14-membered ring which may be saturated, partially unsaturated, or aromatic, optionally containing a total of 1 to 4 identical or different heteroatoms selected from N, O, S, or P, and Cy1 may be optionally fused to a 5- or 6-membered carbocyclic or heterocyclic ring which may be saturated, partially unsaturated, or aromatic, and Cy1 is optionally substituted by one or more groups selected from phenyl, halogen, C1-C4 alkyl, halo-C1-C4 alkyl, -O-C1-C4 alkyl, -OCOO-C1-C4 alkyl, -CO-C1-C4 alkyl, S-C1-C4 alkyl, or N3-C1-C4 alkyl. For example, aziridine, oxirane, thiirane, azetidine, oxetane, thietane, azolidine, oxolane, thiolane, phophorane, piperidine, piperazine, tetrahydropyran, oxane, 1,4-dioxane, morpholine, phosphinane, phenyl, biphenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, 1,4-benzodioxanyl, furan, thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, 1,2 ,3-oxadiazole, 1,2,3-triazole, 1,2,4-triazole, 1,3,4-thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,3,5-triazine, imidazole, benzimidazole, benzoxazole, benzothiazole, indolizine, indole, isoindole, benzofuran, benzothiophene, 1H-indazole, purine, 4H-quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine.

[0035] In the definition of the cyclic group Cy1 used throughout this specification, when the cyclic group refers in general terms to a ring radical, such as pyridyl, thienyl, or indolyl, all available attachment positions are included. Thus, for example, in the definition of Cy1 that does not include limitations on attachment positions, the term pyridyl includes 2-pyridyl, 3-pyridyl, and 4-pyridyl, the term thienyl includes 2-thienyl, and 3-thienyl, and the term indolyl includes 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, and 7-indolyl.

[0036] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes one or more occurrences of said event or circumstance as well as cases where said event or circumstance does not occur. For example, "optionally substituted" means that the referenced group may be substituted or unsubstituted, and both substituted and unsubstituted groups are included in the description, and substitution may occur one or more times.

[0037] The compounds of the present invention can be prepared by a variety of methods, including reacting an appropriate polysubstituted 2-oxa-3-oxoindolizidine derivative bearing a reactive group at the C-5 position with a suitable precursor of the lipid moiety to form a pseudo-amide type linkage, which is referred to as the conjugation step.

[0038] Another aspect of the invention relates to a process for preparing a compound of formula I, where X is -C(=S)-OY, comprising the reaction of a compound of formula II with a compound of formula Y-OH:

[0039] [ka]

[0040] Here, R 1 and Y has the meaning of the compound of formula I where X is -C(=S)-OY.

[0041] Another aspect of the invention relates to a process for preparing a compound of formula I, where X is -C(=Se)-NHY, comprising reacting a compound of formula III with LiAlHSeH:

[0042] [ka]

[0043] Here, R 1 and Y has the meaning of the compound of formula I, where X is -C(=Se)-NHY.

[0044] Another aspect of the invention is a process for preparing a compound of formula I, wherein X is selected from -SO2-NYY', or -SO2-OY, comprising reacting a compound of formula IV with a compound of formula H2NS(=O)2R 2 , H2NS(=O)2NYY', or H2NS(=O)2OR 2 in the presence of a glycosidation promoter, preferably in the presence of boron trifluoride etherate (BF3-Et2O):

[0045] [ka]

[0046] Here, R 1 , Y and Y' have the meanings for compounds of formula I where X is -SO2-NYY' or -SO2-OY.

[0047] Another aspect of the invention relates to a process for preparing a compound of formula I, where X is P(=O)(OY), comprising reacting a compound of formula V with a compound of formula P(=O)(OY):

[0048] [ka]

[0049] Here, R1 and Y has the meaning of the compound of formula I where X is P(=O)(OY)2.

[0050] Another aspect of the invention relates to pharmaceutical compositions comprising at least one compound of formula I or mixtures or combinations thereof.

[0051] The compositions of the present invention optionally comprise at least one pharma- ceutically acceptable carrier, diluent, excipient and / or additive.

[0052] Another aspect of the invention relates to a compound of formula I as defined above or a pharmaceutical composition thereof for use as a medicament.

[0053] Another aspect of the invention relates to the use of a compound of formula I as defined above or a pharmaceutical composition thereof for the manufacture of a medicament.

[0054] Another aspect of the present invention relates to a method for the treatment or prevention of a disease in a subject, particularly a human, in need thereof, which method comprises administering to a subject in need thereof an effective amount of a compound of formula I as defined above or a pharmaceutical composition thereof.

[0055] Another aspect of the invention relates to a compound of formula I' or a pharmaceutical composition thereof for use in the treatment and / or prevention of immune disorders:

[0056] [ka]

[0057] Here, R 1 are each independently -H, -CH2Ph(Bn), -COPh(Bz), -CO-C1-C 12 Alkyl, C1-C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2 has been replaced by; R 2 -OH, -N(R 3)2, -N3, C1-C4 alkyl, or halogen; R 3 are each independently H, or C1-C4 alkyl; X is -C(=S)-OY, -C(=S)-NYY', -C(=O)-NYY', C(=Se)-NHY, -C(=NY)-NHY', -SO2-Y, -SO2-NYY', -SO2-OY, or -P(=O)(OY)2; Y is one or more groups R 4 Optionally substituted -C1-C 25 is alkyl; Y' is H or one or more groups R 4 -C1-C optionally substituted with 25 is alkyl; R 4 -OH, OBn, C1-C 12 Alkyl, -O-C1-C 12 Alkyl, -S-C1-C 12 Alkyl, -N(R 3 )2, -N3, -C(=O)-C1-C 12 alkyl, or Cy1; and Cy1 is a 5-14 membered ring which may be saturated, partially unsaturated, or aromatic and optionally contains a total of 1-4 identical or different heteroatoms selected from N, O, S, or P; Cy1 may be optionally fused to a 5- or 6-membered carbocyclic or heterocyclic ring which may be saturated, partially unsaturated, or aromatic; Cy1 is optionally substituted by one or more groups selected from phenyl, halogen, C1-C4 alkyl, halo-C1-C4 alkyl, -O-C1-C4 alkyl, -OCOO-C1-C4 alkyl, -CO-C1-C4 alkyl, S-C1-C4 alkyl, or N3-C1-C4 alkyl.

[0058] Another aspect of the invention relates to the use of a compound of formula I' as defined above or a pharmaceutical composition thereof for the treatment and / or prevention of immune diseases.

[0059] Another aspect of the present invention relates to a method for the treatment and / or prevention of immune diseases in a subject, particularly a human, in need thereof, which method comprises administering to a subject in need thereof an effective amount of a compound of formula I' as defined above or a pharmaceutical composition thereof.

[0060] In another embodiment, the present invention relates to the use of a compound of formula I' or a pharmaceutical composition thereof for the uses defined above, wherein R 1 are each independently selected from -H, -Bn, -Bz, -CO-C1-C4 alkyl, and -C1-C4 alkyl; R 1 each independently optionally represents one or more groups R 2 and preferably R 1 are each independently selected from -H, -Bn, -Bz, -CO-CH3(Ac), and -C1-C4 alkyl; R 1 each independently optionally represents one or more groups R 2 and more preferably, R 1 are each independently selected from -H, Bn, Bz, Ac, and -C1-C4 alkyl; more preferably, R 1 are each independently selected from -H and Ac.

[0061] In another embodiment, the present invention relates to a compound of formula I' or a pharmaceutical composition thereof for the above defined use, wherein X is selected from -C(=Se)-NHY', -SO2-NYY' or -SO2-OY, more preferably, X is -C(=Se)-NHY' or -SO2-NYY'.

[0062] In another embodiment, the present invention relates to a compound in which Y is optionally selected from one or more groups R 4 -C2-C replaced by 18 alkyl, preferably Y is -C-C 18 is alkyl; or a pharmaceutical composition thereof for the use as defined above.

[0063] In another embodiment, the present invention relates to a compound of formula I' or a pharmaceutical composition thereof for the use as defined above, wherein Y' is H or optionally one or more groups R 4 -C2-C replaced by 18 Preferably, Y' is H and Y is alkyl.

[0064] In another embodiment, the present invention relates to a compound of formula I' or a pharmaceutical composition thereof for the use as defined above, wherein X is selected from -C(=Se)-NHY', -SO2-NYY' or -SO2-OY, more preferably X is -C(=Se)-NHY' or -SO2-NYY'; Y is optionally one or more groups R 4 -C2-C replaced by 18 alkyl, preferably Y is -C-C 18 is alkyl; and Y′ is H or, optionally, one or more groups R 4 -C2-C replaced by 18 and preferably Y′ is H.

[0065] In another embodiment, the present invention relates to a compound of formula I' or a pharmaceutical composition thereof for the above defined uses, selected from:

[0066] [ka] JPEG2024543018000013.jpg250169JPEG2024543018000014.jpg255168JPEG2024543018000015.jpg253169JPEG2024543018000016.jpg144169

[0067] In another embodiment, the present invention relates to a compound of formula I' or a pharmaceutical composition thereof for use as defined above, wherein the immune disease is selected from acute inflammation, chronic disease allergy, cancer chemotherapy, infectious disease, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), immune-mediated hepatitis, autoimmune disease, graft rejection pathology, inflammatory bowel disease, atherosclerosis and airway hyperresponsiveness, preferably, the immune disease is selected from acute inflammation, chronic disease allergy, infectious disease, immune-mediated hepatitis, autoimmune disease, inflammatory bowel disease, atherosclerosis and airway hyperresponsiveness, more preferably, the immune disease is selected from chronic disease allergy, autoimmune disease and airway hyperresponsiveness.

[0068] In another embodiment, the invention relates to a compound of formula I' or a pharmaceutical composition thereof for the use as defined above, wherein the airway hyperresponsiveness is selected from asthma and allergic rhinitis.

[0069] The pharmaceutical composition of the present invention may comprise, as an active ingredient, either one of (a) one of the compounds of formula I'; or (b) a mixture of at least two of the compounds of formula I'. It should be noted that the therapeutic composition of the present invention may optionally further comprise at least one of a pharma- ceutically acceptable carrier, diluent, excipient, or additive.

[0070] As used herein, the term "treatment" means to eliminate, reduce or ameliorate the cause or effects of a disease. For purposes of the present invention, treatment includes, but is not limited to, alleviating, ameliorating or eliminating one or more symptoms of a disease; reducing the extent of a disease; stabilizing the disease state (i.e., not worsening); delaying or slowing the progression of a disease; improving or alleviating the disease state; and remission of a disease (whether partial or total).

[0071] As used herein, "prevention" refers to preventing the onset of a disease in a subject who has a predisposition or risk factors for the disease but who does not yet exhibit symptoms of the disease. Prevention also includes preventing the recurrence of a disease in a subject who has previously suffered from the disease.

[0072] The term "immune disease" refers to any disease in which the immune system is impaired, altered or destroyed and therefore can be treated with an immunotherapeutic approach, i.e., a therapeutic strategy that targets the innate immune sensor. In the case of the compounds and compositions of the present invention, the targeted innate immune sensor is TLR4.Examples of immune diseases that can be treated with the TLR4-targeting immunotherapeutic approach according to the invention include, inter alia, acute inflammation (see, e.g., Swanson et al., Proc. Nat. Acad. USA 2020, 117, 26895-26906; Kuzmich et al., Vaccines 2017, 5, 34), chronic disease allergy (see, e.g., Exp. Ther. Med. 2019, 18, 761-768), cancer chemotherapy (see, e.g., Awasthi, Front Immunol. 2014, 5, 328; Zandi et al., J. Cell. Biochem. 2020, 121, 1623-1634), infectious diseases (see, e.g., Miller et al., Nat. Rev. Microbiol. 2005, 36-46), metabolic syndrome diseases (see, e.g., Jialal et al., Nat. Rev. Microbiol. 2005, 36-46), and the like. al., J.Clin.Endocrinol.Metab.,2014,99,39-48), nonalcoholic fatty liver disease (NAFLD) (e.g., Int.l Immunopharmacol.2020,88,107003), nonalcoholic steatohepatitis (NASH) (e.g., Liu et al. al., Int.immunopharmacol.2019,75,105797), immune-mediated hepatitis (see e.g. Hercun et al.,Front.Immunol.2022,13,907591), autoimmune diseases (e.g. Liu et al. al.,Clinic.Rev.Allerg.Immunol.2014,47,136-147), graft rejection pathology (e.g. Am.J.Transplant.2005;5,969-975), inflammatory bowel disease (e.g. Dejban et al. al., Phytother. Res. 2021, 35, 835-845, atherosclerosis (see, e.g., Li et al., J. Cell. Mol. Med. 2007, 11, 88-95) and airway hyperresponsiveness (see, e.g., Kirtland et al., Front Immunol. 2020, 11, 599083), in particular airway hyperresponsiveness including, among others, asthma and allergic rhinitis.

[0073] Another aspect of the invention relates to a vaccine comprising an effective amount of a compound of formula I' or a pharmaceutical salt thereof and a vaccinal agent.

[0074] The therapeutic composition of the present invention can act as an immunological adjuvant or as a modulator of a co-administered adjuvant, enhancing the immune response induced by a vaccine agent by stimulating the immune system. The enhanced immune response allows the subject to respond more vigorously to the vaccine than if the compound were not administered, while maintaining a good safety profile. In other embodiments, the therapeutic composition can act as an immunodepleting agent, preventing or reducing undesirable immunological reactions to the vaccine in the treated subject.

[0075] In another embodiment, the invention relates to a vaccine as defined above, wherein the compound of the invention is co-administered with an adjuvant selected from an Alum-based adjuvant, including aluminum phosphate gel and aluminum hydroxide gel, or monophosphoryl lipid A (MPL®).

[0076] In another embodiment, the present invention relates to a vaccine as defined above, wherein the vaccinal agent is selected from killed microorganisms, live attenuated microorganisms, toxoids and fragments of inactivated or attenuated microorganisms, synthetic peptide or glycopeptide constructs, ribonucleic acid (RNA)-based vaccines or deoxyribonucleic acid (DNA)-based vaccines.

[0077] In another embodiment, the present invention relates to a vaccine as defined above, wherein the microorganism of the vaccinal agent is a virus, a bacterium or a fungus.

[0078] In another embodiment, the invention relates to a vaccine as defined above, wherein the toxoid is a tetanus or diphtheria toxoid.

[0079] In another embodiment, the present invention relates to a vaccine as defined above, wherein the RNA is messenger RNA (mRNA).

[0080] In another embodiment, the present invention relates to a vaccine as defined above, wherein the DNA is plasmid DNA (pDNA).

[0081] In another embodiment, the RNA- or DNA-based vaccine comprises a pharma- ceutically acceptable delivery system.

[0082] In another embodiment, the delivery system is non-viral or viral based.

[0083] In another embodiment, the non-viral based delivery system is selected from cationic lipids, cationic polymers, molecular-based systems, and nanoparticle-based systems.

[0084] In another embodiment, the viral-based delivery system is selected from a modified adenovirus system and a modified lentivirus system.

[0085] Further, another aspect of the present invention relates to a method for the preparation of a medicament for the treatment of a pathological disorder or condition in a subject in need thereof, comprising the steps of: (A) providing an immunomodulatory agent comprising any one of: (a) at least one compound of formula I'; (b) a mixture of at least two compounds of formula I'; and (B) admixing the immunomodulatory compound provided in step (A) with a pharma- ceutically acceptable carrier.

[0086] In view of the above, the present invention provides novel glycolipid mimetics of formula I that are metabolically stable and can be selectively modified to optimize TLR4 antagonist or agonist behavior. The present invention also aims to provide a method for preparing said glycolipid mimetics with complete α-anomeric stereoselectivity. Furthermore, the present invention provides pharmaceuticals, such as anti-inflammatory agents or vaccine formulations, containing the glycolipid mimetics of formula I'.

[0087] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs. Methods and materials similar or equivalent to those described herein may be used in the practice of this invention. Throughout this specification and claims, the word "comprises" and variations thereof are not intended to exclude other technical features, additives, ingredients, or steps. Additional objects, advantages, and features of the present invention will become apparent to those skilled in the art upon examination of this specification or may be learned by practice of the present invention. The following examples and figures are provided for illustrative purposes and are not intended to limit the present invention.

[0088] BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. Suppression of LPS-induced inflammation (in vitro spleen cells). Spleen cells were treated simultaneously with the compound of the present invention and LPS to evaluate the inhibitory function of the compound against LPS-induced inflammation. Some compounds showed significant inhibitory function.

[0089] Figure 2. Suppression of LPS-induced inflammation in bone marrow derived macrophages (BMDM in vitro). Compounds 4 and 14 were evaluated for their ability to suppress LPS-induced inflammation in bone marrow derived macrophages (BMDM), both showing significant suppression of IL-6 at 50 μM and TNFα at 10 μM and 50 μM.

[0090] Figure 3. Suppression of LPS-induced inflammation in vivo. The ability of compound 29 to suppress LPS-induced inflammation in B6 mice in vivo was evaluated as shown in the scheme. Compound 29 was shown to significantly suppress LPS-induced serum TNFα when injected twice within a 30-minute period after LPS treatment.

[0091] Figure 4. The MAPK family ERK and p38, as well as STAT3, are inhibited by novel compounds. Using multiplex bead arrays, we investigated how the novel compounds exert their inhibitory effects from the perspective of signal transduction, using compounds 4 and 14, which are representative compounds of the present invention. Compared with LPS treatment alone, compounds 4 and 14 significantly reduced the phosphorylation of mitogen-activated protein kinases (MAPKs), ERK and p38, but not JNK, 30 minutes after treatment. A significant reduction in the phosphorylation of STAT3 by compound 14 was also observed 30 minutes after treatment.

[0092] Figure 5. Inhibition of αGalCer-induced inflammation (in vitro spleen cells). Spleen cells were treated simultaneously with the compound of the present invention and αGalCer to evaluate the inhibitory function of the compound against αGalCer-induced inflammation. Some compounds showed significant inhibitory function.

[0093] Figure 6. Shows the immune stimulating function of compounds (spleen cells in vitro). Spleen cells were treated with the compounds of the present invention alone to evaluate the immune stimulating function of the compounds. Only compound 29 induced significant IFNγ secretion, and none of the compounds induced significant IL-4 secretion.

[0094] Figure 7. Inhibition of ovalbumin (OVA)-induced airway hyperresponsiveness (AHR) in vivo. The in vivo Th2 inflammation suppression ability of selected compounds 14 and 29 was evaluated using an OVA-induced AHR mouse model. Compound 29 was confirmed to significantly suppress AHR.

[0095] Figure 8. Inhibition of OVA-induced airway inflammation (BALF) in vivo. Bronchoalveolar lavage fluid (BALF) from mice in OVA-induced AHR experiments was examined for their IL-13 and IL-4 levels. Compound 29 was shown to significantly inhibit both IL-13 and IL-4 levels.

[0096] Figure 9. Inhibition of OVA-induced airway inflammation in vivo (lung protein). Lungs from mice in OVA-induced AHR experiments were examined for IL-13 and IL-4 protein levels. Only compound 29 showed significant inhibition of IL-13, and no significant inhibition of IL-4 was observed among the compounds tested.

[0097] Figure 10. Inhibition of OVA-induced airway inflammation in vivo (lung mRNA). Lungs from mice in the OVA-induced AHR experiment were examined for their IL-13 and IL-4 mRNA levels. Both compounds 14 and 29 significantly inhibited IL-13 and IL-4 mRNA levels.

[0098] Figure 11. Adjuvant function of compounds in vivo. The adjuvant function of selected compound 29 in vivo was evaluated by measuring serum levels of IFNγ and IL-4 induced after injection in B6 mice. Compound 29 showed significant ability to induce both IFNγ and IL-4 2 hours after injection, and also showed significant detectable levels of IFNγ 18 hours after injection.

[0099] [Example] The following examples are intended to illustrate embodiments of the present invention and are not intended to be limiting.

[0100] (method) All reagents and solvents used in the preparations disclosed in the following examples were purchased commercially and used without further purification unless otherwise specified. Thin-layer chromatography (TLC) was performed using Silica gel 60F. 254Visualization with UV light (lambda 254 nm) and charring with 10% ethanolic H2SO4, 0.1% ethanolic ninhydrin, and heating at 100 °C were performed on Merck-coated aluminum sheets. For preparative purposes, column chromatography was performed on a Silice 60 A.CC Chromagel (SDS 70-200, 35-70 μm). Optical rotation was measured with a Jasco P-2000 polarimeter at 20 ± 2 °C in 1 cm tubes using a sodium lamp (lambda 589 nm). Elemental analysis was performed at the Instituto de Investigaciones Quimicas (Seville, Spain) using elemental analyzers Leco CHNS-932 o Leco TruSpec CHN. NMR experiments were performed with a Bruker 300 ADVANCE and 500 DRX at 300 (75.5), 500 (125.7, 202) MHz. 1D TOCSY, 2D COSY, HMQC and HSQC experiments were used to aid in NMR assignments. Chemical shift values ​​are given in parts per million (ppm) using the solvent tetramethylsilane (CDCl3) as the internal standard. Coupling constant (J) values ​​are measured in Hz. Abbreviations indicating signal multiplicity are s (singlet), bs (broad singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). Mass spectra (high resolution mass spectra) were obtained using a Bruker Daltonics Esquire6000. TM The experiments were carried out on a LTQ-Orbitrap XL ETD. Samples were introduced through a solid probe heated to 30-280 °C. ESI (electrospray ionization) was used as the ionization source, and methanol was used as the solvent. Samples were directly injected using a Cole-Parmer syringe at a flow rate of 2 μl / min. Ions were scanned between 300 and 3000 Da at a scan rate of 13000 Da / s with unitary resolution using resonance ejection at a multipolar resonance of one-third of the radio frequency (Ω = 781.25 kHz).

[0101] (material) In the illustrative disclosure, the following precursors used in the synthesis of certain compounds of the invention were obtained by known methods: (1R)-1,2,3,4-Tetra-O-acetyl-5N,6O-oxomethylidene nojirimycin 35 was prepared as described by VM Diaz Perez, MI Garcia Moreno, C. Ortiz Mellet, J. Fuentes, JC Diaz Arribas, FJ Canada and JM Garcia Fernandez, J. Org. Chem., 2000, 65, 136-143.

[0102] [ka]

[0103] N-(octyl)sulfamide was prepared as described by K. Suthagar, AJA Watson, BL Wilkinson and AJ Fairnbanks, Eur. J. Med. Chem., 2015, 102, 153-166.

[0104] [ka]

[0105] N-(dodecyl)sulfamide was prepared as described by K. Suthagar, AJA Watson, BL Wilkinson and AJ Fairnbanks, Eur. J. Med. Chem., 2015, 102, 153-166.

[0106] [ka]

[0107] O-octylsulfamate was prepared as described by S. Ahmed, K. James, CP Owen, CK Patela and L. Sampson, Bioorg. Med. Chem. Letters 2002, 12, 1279-1282.

[0108] [ka]

[0109] O-Dodecylsulfamate was prepared as described by J.-Y. Winum, D. Vullo, A. Casini, J.-L. Montero, A. Scozzafava, and C.T. Supuran, J. Med. Chem. 2003, 46, 5471-5477.

[0110] [ka]

[0111] O-Hexadecylsulfamate was prepared as described in J.-Y. Winum, D. Vullo, A. Casini, J.-L. Montero, A. Scozzafava, and C.T. Supuran, J. Med. Chem. 2003, 46, 5471-5477.

[0112] [ka]

[0113] Octylsulfonamide was prepared as described in D. Zhong, D. Wu, Y. Zhang, Z. Lu, M. Usman, W. Liu, X. Lu and W.-B. Liu, Org. Lett. 2019, 21, 5808-5812.

[0114] [ka]

[0115] α-GalCer (αGC, KRN7000) was purchased from Funakoshi (Tokyo, Japan). RPMI1640, DMEM, newborn calf serum (NBCS) and red blood cell (RBC) lysis buffer were purchased from Gibco (Waltham, MA, USA). Fetal bovine serum (FBS) was purchased from HyClone (Logan, UT, USA). Recombinant mouse IL-2 and GM-CSF were purchased from BioLegend (San Diego, CA, USA) and PeproTech (Rocky Hill, NJ, USA). Recombinant human IL-2 was purchased from eBioscience (San Diego, CA, USA). Ovalbumin (OVA) was purchased from Worthington Biochemicals (Freehold, NJ, USA).

[0116] (mouse) C57BL / 6 and BALB / c female mice aged 8–10 weeks were purchased from the National Laboratory Animal Center (Taipei, Taiwan). All animals were kept under specific pathogen-free conditions.

[0117] (In vitro culture of mouse splenocytes and human peripheral blood mononuclear cells (PBMCs)) Whole spleens were surgically removed from mice and mechanically dissociated into single-cell suspensions of splenocytes, which were cultured in complete RPMI 1640 medium (cRPMI).Human peripheral blood mononuclear cells (PBMCs) from healthy volunteers were obtained from whole blood by gradient centrifugation using Histopaque-1077 (Sigma-Aldrich).

[0118] (In vivo treatment) For ovalbumin (OVA) challenge, mice were sensitized intraperitoneally (ip) with 50 μg OVA in 2% alhydrogel adjuvant (InvivoGen). On day 7 after sensitization, mice were sensitized with 50 μg OVA three times, daily or every other day. Mice were sacrificed the day after the final OVA challenge.

[0119] (Measurement of Airway Hyperresponsiveness (AHR)) Mice were anesthetized with 100 mg pentobarbital (Sigma-Aldrich) per kg body weight, tracheotomized, and mechanically ventilated via a FinePointe RC system (Buxco Research Systems, Wilmington, NC). Pulmonary function was assessed by measuring pulmonary resistance and dynamic compliance in response to increasing doses of aerosolized methacholine (1.25–40 mg / mL, Sigma-Aldrich).

[0120] (Collection and analysis of bronchoalveolar lavage fluid (BALF)) After exposing the trachea, the lungs were lavaged twice with 1 mL of PBS supplemented with 2% fetal calf serum (FCS). BALF was pooled, and BAL cells were pelleted by centrifugation and fixed on cytospin slides. Slides were stained with Diff-Quik solution (Polysciences Inc), and BAL differential cell counts were calculated.

[0121] (Flow Cytometry) Single cell suspensions were stained with the fixable viability dye eFluor® 780 (eBioscience) for 30 min at 4°C and Fc receptors were blocked with anti-CD16 / 32 (BioLegend) blocking antibody before surface staining with monoclonal antibodies.

[0122] (statistics) Data were analyzed using GraphPad Prism (GraphPad Software, San Diego, CA, USA). Statistical analysis was performed using Student's t-test and two-way analysis of variance (ANOVA).

[0123] [Example 1. Synthesis of Compound 1] Compound 1 was prepared by the reaction of triethylphosphite (P(=O)(OEt)3) with glycosyl azide derivative 36. Compound 36 was prepared sequentially from compound 35 as depicted in Scheme 1 according to the procedures described below.

[0124] [ka]

[0125] To a solution of 35 (100 mg, 0.267 mmol) in dry DCM (5 mL) cooled to 0 °C, a 33% solution of HBr in AcOH (0.18 mL) was slowly added and the mixture was stirred for 5 min. The reaction was then diluted with DCM (10 mL), washed with aqueous NaHCO3, dried (MgSO4) and the solvent was evaporated under reduced pressure. The bromo derivative thus produced was used directly in the next reaction without further purification. To a solution of the crude bromide in dry DMF (6.6 mL) was added NaN3 (26 mg, 0.40 mmol) and the reaction mixture was stirred under Ar atmosphere for 2 h. The solvent was evaporated under reduced pressure and the residue was dissolved in EtOAc (20 mL), washed with H2O (20 mL), dried (MgSO4) and purified by column chromatography (1:4 → 1:3 EtOAc-cyclohexane) to give 36. Yield: 82 mg (86% yield over two steps). R f 0.56 (2:1 EtOAc-cyclohexane). [α] D -12.4(c1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ=5.25(d,1H,J 1,2 =4.1Hz H-1), 5.18(dd,1H,J 3,4 =10.4Hz,J 4,5 =6.6Hz,H-4),5.09-5.03(m,2H,H-2,H-3),4.47(t,1H,J 6a,6b =8.9Hz,J, 5,6a =8.5Hz,H-6a),4.21(t,1H,H-6b),3.97(m,1H,H-5),2.13,2.09,2.06(3s,9H,CH3CO). 13C NMR (75.5 MHz, CDCl3): δ = 169.8-168.5 (CO ester), 156.5 (CO carbamate), 72.7-72.6 (C-3, C-4), 71.8 (C-2), 68.4 (C-5), 67.6 (C-6), 52.6 (C-1), 20.6 (CH3). ESIMS: m / z = 379.1 [M+Na] + Anal.calcd.for C 13 H 16 N4O8:C43.82,H4.53,N15.73. Found:C43.89,H4.60,N15.57.

[0126] In the next step, triethylphosphite (0.23 mmol, 1 eq) was added to a solution of 36 (80 mg, 0.23 mmol) in dry DCM (1 mL) under Ar atmosphere. The mixture was stirred for 18 h. After complete formation of the phosphoramidate (TLC), H2O (1 mL) was added to the reaction mixture and the solution was stirred for another 5 h. The layers were separated and the organic layer was washed twice with brine, dried (MgSO4) and the solvent was evaporated under reduced pressure. The resulting residue was purified by column chromatography (eluent 4:1 acetone-toluene → MeOH) to give 1. Yield: 86 mg (84%). R f 0.51 (1:1 acetone-toluene). [α] D -3.73(c1.0 in MeOH). 1 H NMR(300MHz,CDCl3):δ5.32(t,1H,J 2,3 =J 3,4 =9.3Hz,H-3),5.12(m,1H,H-4,H-2),4.79(dd,1H,J 1,2 =9.6Hz,J 1,P =11.2Hz,H-1),4.36(dd,1H,J 6a,6b =9.5Hz,J 5,6a =6.9Hz,H-6a),4.19(dd,1H,J 5,6b =2.7Hz H-6b),4.09(m,4H,CH2O),4.03(m,1H,H-5),2.08(s,6H,CH3CO),2.06(s,6H,CH3CO),2.00(s,3H,CH3CO),1.3(m,6H,CH3). 13C NMR (100.6 MHz, CDCl3): δ 170.3, 169.9, 169.8 (CO ester), 156.7 (CO carbamate), 72.7 (C-3), 71.0 (C-2), 69.8 (C-4), 64.7 (C-1, C-6), 63.0 (CHO), 55.9 (C-5), 19.3 (CHCO), 19.1 (CHCO), 19.0 (CHCO), 15.1-14.9 (CH). 31 P NMR (121.5MHz, CDCl3): δ=6.49. ESIMS:m / z=489.2[M+Na] + Anal.calcd. for C 17 H 27 N2O 11 P:C43.78,H5.84,N6.01. Found: C43.87, H5.89, N5.67.

[0127] [Example 2. Synthesis of compound 2] Compound 2 was obtained by treating a solution of 1 (65 mg, 0.139 mmol) in MeOH (3.5 mL) with 1 M NaOMe in MeOH (56 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation, and purification by column chromatography (4:1 acetone-toluene → MeOH). Yield: 45 mg (95%). f 0.50(30:10:1 DCM-MeOH-H2O). [α] D -1.09(c 1.0 in MeOH). 1 H NMR(500MHz,CD3OD):δ4.36(bd,1H,H-1),4.31(m,2H,H-2,H-4),4.13(m,4H,CH2O) ,3.58(m,1H,H-5),3.32(m,2H,H-6a,H-6b),3.24(bdd,1H,H-3),1.31(bt,6H,CH3). 13 C NMR (125.7MHz, CD3OD): δ157.4 (CO carbamate), 76.8 (C-3), 73.1 (C-4), 71.6 (C-2), 67.1 (C-6), 64.9 (C-1), 62.7 (CH2O), 58.3 (C-5), 15.0 (CH3). ESIMS:m / z=363.1[M+Na] +Anal.calcd. for C 11 H 21 N2O8P:C38.83,H6.22,N8.23. Found:C38.73,H6.02,N8.01.

[0128] [Example 3. Synthesis of compound 3] To a solution of 36 (80 mg, 0.23 mmol) in dry DCM (1 mL) was added trioctyl phosphite (0.23 mmol, 1 eq) under Ar atmosphere. The mixture was stirred for 18 h. After complete formation of the phosphoramidate (TLC), H2O (1 mL) was added to the reaction mixture and the solution was stirred for another 5 h. The layers were separated and the organic layer was washed twice with brine, dried (MgSO4) and the solvent was evaporated under reduced pressure. The resulting residue was purified by column chromatography (eluent 1:3→1:1→4:1 EtOAc-cyclohexane). Yield: 100 mg (70%). R f 0.25 (1:1 EtOAc-cyclohexane). [α] D -2.12(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.23(t,1H,J 2,3 =J 3,4 =9.5Hz,H-3),5.07(t,1H,J 4,5 =9.5,H-4),5.06(t,1H,H-2),4.73(bdd,1H,J 1,NH =11.5Hz,J 1,2 =10.8Hz,H-1),4.54(bdd,1H,J NH,P =9.9Hz,NH),4.28(bdd,1H,H-6a),4.15(m,1H,H-6b),3.9(m,4H,CH2O),3.75(m,1H,H-5),2.07,2.01(2s,9H,CH3CO),1.76-0.70(m,30H,CH2,CH2CH3). 13C NMR (75.5 MHz, CDCl3): δ 169.8, 169.6, 169.5 (CO ester), 156.4 (CO carbamate), 72.4 (C-3), 70.4 (C-2), 69.7 (C-4), 67.4 (CHO), 65.6 (C-1), 64.5 (C-6), 56.4 (C-5), 46.6-10.5 (CHCO, CH, CHCH). ESIMS: m / z = 635.4 [M+H] + Anal.calcd. for C 29 H 51 N2O 11 P:C54.88,H8.10,N4.41. Found: C55.12, H7.96, N4.41.

[0129] [Example 4. Synthesis of compound 4] Compound 4 was obtained by treating a solution of 3 (100 mg, 0.157 mmol) in MeOH (4 mL) with 1 M NaOMe in MeOH (63 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation, and purification by column chromatography (50:10:1 DCM-MeOH-H2O). Yield: 68 mg (85%). f 0.70(50:10:1 DCM-MeOH-H2O). [α] D -6.55(c 1.0 in DCM). 1 H NMR (500MHz, CDCl3): δ4.26(bd,1H,H-1),4.21(bt,2H,H-2,H-4),3.97(m,4H,CH2O),3.43(bt,1H,J 4,5 =J 5,6a =8.49Hz,H-5),3.31(m,2H,H-6a,H-6b),3.23(t,1H,J 2,3 =J 3,4 =9Hz,H-3),1.6-0.7(m,30H,CH2,CH2CH3). 13 C NMR (125.7MHz, CDCl3): δ157.5 (CO carbamate), 73.2 (C-3), 71.2 (C-6), 67.4 (C-2), 67.1 (C-4), 65.6 (CH2O), 65.0 (C-1), 58.4 (C-5), 45.7-10.5 (CH2, CH2CH3). 31P NMR (121.5MHz, CDCl3): δ=6.83. ESIMS:m / z=531.3[M+Na] + Anal.calcd. for C 23 H 45 N2O8P:C54.32,H8.92,N5.51. Found:C54.07,H8.71,N5.22.

[0130] [Example 5. Synthesis of compound 5] To a solution of 36 (80 mg, 0.23 mmol) in dry DCM (1 mL) was added tridodecyl phosphite (0.23 mmol, 1 eq) under Ar atmosphere. The mixture was stirred for 18 h. After complete formation of the phosphoramidate (TLC), H2O (1 mL) was added to the reaction mixture and the solution was stirred for another 5 h. The layers were separated and the organic layer was washed twice with brine, dried (MgSO4) and the solvent was evaporated under reduced pressure. The resulting residue was purified by column chromatography (eluent 1:3→4:1 EtOAc-cyclohexane). Yield: 82 mg (79%). R f 0.45 (2:1 EtOAc-cyclohexane). [α] D +8.01(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.24(t,1H,J 2,3 =J 3,4 =9.5Hz,H-3),5.07(t,1H,J 4,5 =9.6,H-4),5.06(t,1H,H-2),4.74(bdd,1H,J 1,NH =11.7Hz,J 1,2 =10.8Hz,H-1),4.53(bdd,1H,J NH,P =9.4Hz,NH),4.29(dd,1H,J 6a,6b =9.0Hz,J 5,6a =6.5Hz,H-6a),4.16(bdd,1H,H-6b),3.96(m,4H,CH2O),3.75(m,1H,H-5),2.07,2.02(2s,9H,CH3CO),1.65-0.7(m,50H,CH2,CH2CH3). 13C NMR (75.5 MHz, CDCl3): δ 169.8, 169.7, 169.5 (CO ester), 156.4 (CO carbamate), 72.4 (C-3), 70.4 (C-2), 69.7 (C-4), 67.0 (CH2O), 65.6 (C-1), 64.5 (C-6), 56.5 (C-5), 31.9-34.0 (CH3CO, CH2, CH2CH3). 31 P NMR (121.5MHz, CDCl3): δ=5.99. ESIMS:m / z=769.4[M+Na] + Anal.calcd. for C 37 H 67 N2O 11 P:C59.50,H9.04,N3.75. Found: C59.39, H9.11, N3.62.

[0131] [Example 6. Synthesis of compound 6] Compound 6 was obtained by treating a solution of 5 (80 mg, 0.107 mmol) in MeOH (2.7 mL) with 1 M NaOMe in MeOH (43 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation, and purification by column chromatography (70:10:1 DCM-MeOH-H2O). Yield: 65 mg (97%). f 0.70(70:10:1 DCM-MeOH-H2O). [α] D +10.70(c 1.0 in DCM). 1 H NMR (500MHz, CDCl3): δ4.29(bdd,1H,H-1),4.23(m,2H,H-2,H-4),3.98(m,4H,CH2O),3.43(bt,1H,H-5),3.33(m,2H,H-6a,H-6b),3.24(t,1H,J 2,3 =J 3,4 =9.2Hz,H-3),1.62-0.84(m,50H,CH2,CH2CH3). 13 C NMR (125.7MHz, CDCl3): δ157.6 (CO carbamate), 73.0 (C-3), 71.1 (C-6), 67.3 (C-2), 67.2 (C-4), 67.1 (CH2O), 65.1 (C-1), 58.3 (C-5), 31.8-13.9 (CH2, CH2CH3).31 P NMR (121.5MHz, CDCl3): δ=7.07. ESIMS:m / z=643.4[M+Na] + Anal.calcd. for C 31 H 61 N2O8P:C59.98,H9.90,N4.51. Found: C59.71, H9.80, N4.19.

[0132] [Example 7. Synthesis of compound 7] To a solution of 35 (50 mg, 0.133 mmol) in dry DCM (1 mL) was added commercially available N-(butyl)sulfamide (0.159 mmol) and BF3·OEt2 (33 μL, 0.266 mmol) under Ar atmosphere at 0 °C. The mixture was stirred for 16 h. After complete formation of the product (TLC), Et3N (0.15 mL) was added and the mixture was stirred for 10 min and concentrated. The resulting residue was purified by column chromatography (eluent 1:2→1:1 EtOAc-cyclohexane) to give 7. Yield: 48 mg (77%). R f 0.60 (2:1 EtOAc-cyclohexane). [α] D +46.10(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.45(t,1H,J 2,3 =J 3,4 =9.5Hz,H-3),5.45(bdd,1H,J 1,2 =5.0Hz,J 1,NH =3.0Hz,H-1),5.39(d,1H,NH),5.16(t,1H,J NH,CH2 =5.8Hz,NH-CH2),5.06(dd,1H,H-2),4.94(t,1H,J 4,5 =9.4Hz,H-4),4.46(bdd,1H,J 6a,6b =J 5,6a =8.8Hz,H-6a),4.27(bdd,1H,H-6b),4.15(m,1H,H-5),2.96(m,2H,CH2N),2.09, 2.04,2.02(3s,9H,CH3CO),1.52(m,2H,CH2),1.35(m,2H,CH2),0.89(t,3H,CH3). 13C NMR (75.5 MHz, CDCl3): δ 169.1, 168.8, 168.1 (CO ester), 155.1 (CO carbamate), 71.4 (C-4), 68.1 (C-2), 68.1 (C-3), 66.1 (C-6), 58.7 (C-1), 50.5 (C-5), 42.0 (CH2N), 19.5 (CH2,CH3CO), 18.7 (CH2), 12.5 (CH3). ESIMS: m / z = 488.1 [M+Na] + Anal.calcd. for C 17 H 27 N3O 10 S:C43.87,H5.85,N9.03,S6.89. Found: C43.81, H5.77, N8.89, S6.61.

[0133] [Example 8. Synthesis of compound 8] Compound 8 was obtained by treating a solution of 7 (66 mg, 0.141 mmol) in MeOH (3.5 mL) with 1 M NaOMe in MeOH (56 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Yield: 48 mg (quantitative). f 0.30(80:10:1 DCM-MeOH-H2O). [α] D +32.53(c 1.0 in MeOH). 1 H NMR(300MHz,CD3OD):δ5.19(d,1H,J 1,2 =4.7Hz,H-1),4.51(t,1H,J 6a,6b =8.7Hz,H-6a),4.29(dd,1H,J 5,6a =5.2Hz,H-6b),3.83(m,1H,H-5),3.56(m,2H,H-2,H-3),3.32(m,1H,H-4),3.02(m,2H,CH2N),1.55(m,2H,CH2),1.40(m,2H,CH2),0.96(t,3H,CH3). 13C NMR (75.5MHz, CD3OD): δ156.9 (CO carbamate), 73.8 (C-4), 73.09 (C-2), 70.0 (C-3), 66 .5(C-6),62.9(C-1),53.2(C-5),42.2(CH2N),31.3(CH2),19.5(CH2),12.6(CH3). ESIMS:m / z=362.13[M+Na] + Anal.calcd. for C 11 H 21 N3O7S:C38.93,H6.24,N12.38,S9.45. Found: C38.76, H6.04, N12.11, S9.18.

[0134] [Example 9. Synthesis of compound 9] To a solution of 35 (50 mg, 0.133 mmol) in dry DCM (1 mL) was added N-(octyl)sulfamide (0.159 mmol) and BF3·OEt2 (33 μL, 0.266 mmol) under Ar atmosphere at 0 °C. The mixture was stirred for 16 h. After complete formation of the product (TLC), Et3N (0.15 mL) was added and the mixture was stirred for 10 min and concentrated. The resulting residue was purified by column chromatography (eluent 1:3→1:2→1:1 EtOAc-cyclohexane). Yield: 48 mg (70%). R f 0.70 (2:1 EtOAc-cyclohexane). [α] D +54.92(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.49(t,1H,J 2,3 =J 3,4 =9.5Hz,H-3),5.49(bdd,1H,J 1,2 =5.0Hz,J 1, NH =2.7Hz,H-1),5.41(d,1H,NH),5.19(t,1H,J NH,CH2 =5.8Hz,NH-CH2),5.10(dd,1H,H-2),4.98(t,1H,J 4,5 =9.5Hz,H-4),4.50(t,1H,J 6a,6b =J 5,6a=8.5Hz,H-6a),4.30(t,1H,H-6b),4.18(m,1H,H-5),2.98(m,2H,CH2N),2.13,2.08,2.06(3s,9H,CH3CO),1.73-0.8(m,15H,CH2,CH2CH3). 13 C NMR (75.5 MHz, CDCl3): δ 170.1, 169.7, 169.0 (CO ester), 156.2 (CO carbamate), 72.5 (C-4), 69.2 (C-2), 69.1 (C-3), 67.2 (C-6), 59.7 (C-1), 51.5 (C-5), 43.3 (CH2N), 31.7-14.0 (CH3CO, CH2, CH2CH3). ESIMS: m / z = 544.2 [M+Na] + Anal.calcd. for C 21 H 35 N3O 10 S:C48.36,H6.76,N8.06,S6.15. Found: C48.48, H6.85, N7.85, S5.92.

[0135] [Example 10. Synthesis of compound 10] Compound 10 was obtained by treating a solution of 9 (40 mg, 0.076 mmol) in MeOH (1.9 mL) with 1 M NaOMe in MeOH (30 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Yield: 30 mg (quantitative). f 0.40(80:10:1 DCM-MeOH-H2O). [α] D +33.97(c 1.0 in acetone). 1 H NMR(300MHz,CD3OD):δ5.19(d,1H,J 1,2 =4.7Hz,H-1),4.51(t,1H,J 6a,6b =8.7Hz,H-6a),4.29(dd,1H,J 5,6b =5.2Hz,H-6b),3.83(m,1H,H-5),3.57(m,2H,H-2,H-3),3.33(m,1H,H-4),3.01(m,2H,CH2N),1.57-0.91(m,15H,CH2,CH2CH3). 13C NMR (75.5MHz, CDCl3): δ156.9 (CO carbamate), 73.8 (C-4), 73.0 (C-2), 70.0 (C-3), 66.5 (C-6), 62.9 (C-1), 53.2 (C-5), 42.2 (CH2N), 31.5-13.0 (CH2, CH2CH3). ESIMS:m / z=418.21[M+Na] + Anal.calcd. for C 15 H 29 N3O7S:C45.56,H7.39,N10.63,S8.11. Found: C45.39, H7.22, N10.36, S7.84.

[0136] [Example 11. Synthesis of compound 11] To a solution of 35 (50 mg, 0.133 mmol) in dry DCM (1 mL) was added N-(dodecyl)sulfamide (0.159 mmol) and BF3·OEt2 (33 μL, 0.266 mmol) under Ar atmosphere at 0 °C. The mixture was stirred for 16 h. After complete formation of the product (TLC), Et3N (0.15 mL) was added and the mixture was stirred for 10 min and concentrated. The resulting residue was purified by column chromatography (eluent 1:2 EtOAc-cyclohexane). Yield: 60 mg (78%). R f 0.43 (1:1 EtOAc-cyclohexane). [α] D +30.83(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.48(t,1H,J 2,3 =J 3,4 =9.5Hz,H-3),5.49(bdd,1H,J 1,2 =5.0Hz,J 1,NH =2.9Hz,H-1),5.28(d,1H,NH),5.16(t,1H,J NH,CH2 =5.8Hz,NH-CH2),5.10(dd,1H,H-2),4.97(t,1H,J 4,5 =9.4Hz,H-4),4.50(t,1H,J 6a,6b =J 5,6a=8.6Hz,H-6a),4.30(t,1H,H-6b),4.18(m,1H,H-5),2.98(m,2H,CH2N),2.13,2.08,2.06(3s,9H,CH3CO),1.66-0.89(m,25H,CH2,CH2CH3). 13 C NMR (75.5 MHz, CDCl3): δ 170.0, 169.7, 169.0 (CO ester), 156.2 (CO carbamate), 72.5 (C-4), 69.2 (C-2), 69.1 (C-3), 67.3 (C-6), 59.7 (C-1), 51.5 (C-5), 43.4 (CH2N), 31.9-14.1 (CH3CO, CH2, CH2CH3). ESIMS: m / z = 600.3 [M+Na] + Anal.calcd. for C 25 H 43 N3O 10 S:C51.98,H7.50,N7.27,S5.55. Found: C52.20, H7.63, N7.33, S5.32.

[0137] [Example 12. Synthesis of compound 12] Compound 12 was obtained by treating a solution of 11 (40 mg, 0.103 mmol) in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Yield: 47 mg (quantitative). f 0.50(80:10:1DCM-MeOH-H2O). [α] D +20.83(c 1.0 in acetone). 1 H NMR(300MHz,1:5CDCl3-CD3OD):δ5.15(d,1H,J 1,2 =4.7Hz,H-1),4.48(t,1H,J 6a,6b =8.7Hz,H-6a),4.25(dd,1H,J 5,6b =5.4Hz,H-6b),3.81(m,1H,H-5),3.53(m,2H,H-2,H-3),3.29(m,1H,H-4),2.90(m,2H,CH2N),1.54-0.86(m,25H,CH2,CH2CH3). 13C NMR(75.5MHz,1:5 CDCl3-CD3OD): δ156.7 (CO carbamate), 73.6 (C-4), 72.8 (C-2), 69.6 (C-3), 66.3 (C-6), 62.2 (C-1), 52.8 (C-5), 42.3 (CH2N), 31.4-12.9 (CH3CO, CH2, CH2CH3). ESIMS:m / z=474.24[M+Na] + Anal.calcd. for C 19 H 37 N3O7S:C50.54,H8.26,N9.31,S7.10. Found: C50.26, H7.97, N9.00, S6.84.

[0138] [Example 13. Synthesis of compound 13] Compound 13 was obtained by coupling 35 with N-hexadecylsulfamide 38. Precursor 37 was prepared according to Scheme 2 from chlorosulfonyl isocyanate and hexadecylamine as described below.

[0139] [ka]

[0140] To a solution of commercially available chlorosulfonyl isocyanate (4 mmol) in dry DCM (1.5 mL), t BuOH (6 mmol, 568 μL) was added slowly at 0° C. under Ar atmosphere. The mixture was stirred at 0° C. for 30 min. Hexadecylamine (4 mmol, 1 eq) and dry Et3N (1.5 eq) were dissolved in dry DCM (1.5 mL) and added to the above solution. The reaction mixture was stirred at room temperature for 16 h. After complete formation of the product, the solvent was evaporated under reduced pressure and the residue was dissolved in DCM, washed with aqueous NaHCO3 (3×20 mL), brine (3×20 mL) and dried (MgSO4). The resulting residue was purified by column chromatography using DCM to give the Boc-protected sulfamide derivative 37. Yield: 117 mg (15%). R f 0.2(DCM). [α] D -2.07(c 1.0 in DCM). 1H NMR(300MHz,CDCl3):δ5.31(s,1H,NHCH2),3.07(t,2H,J H,H =7.0Hz,CH2N),1.72-1.27(m,28H,CH2),0.89(t,3H,CH2CH3). 13 C NMR (75.5MHz, CDCl3): δ150.2(CO), 83.7(CMe3), 43.9-14.1(CH2,CH2CH3,CMe3). ESIMS:m / z=443.3[M+Na] + Anal.calcd. for C 21 H 44 N2O4S:C59.96,H10.54,N6.66,S7.62. Found: C60.19, H10.71, N6.48, S7.45.

[0141] Compound 38 was obtained by treating 37 (60 mg, 0.142 mmol) with DCM-TFA (1:8, 2 mL) for 5 h, followed by purification by column chromatography (60:10:1 DCM-MeOH-H2O). Yield: 45 mg (quantitative). f 0.60(50:10:1 DCM-MeOH-H2O). [α] D -9.20(c 1.0 in DCM). 1 H NMR (300MHz, DMSO-d6): δ5.41(s,1H,NH2),3.31(s,1H,NHCH2),2.82(m,2H,CH2N)1.44-0.85(m,33H,CH2,CH2CH3). 13 C NMR (75.5MHz, DMSO-d6): δ43.0 (CH2N), 31.7-14.4 (CH2, CH2CH3). ESIMS:m / z=319.1[MH] - Anal.calcd. for C 16 H 36 N2O2S:C59.95,H11.32,N8.74,S10.00. Found: C59.82, H11.26, N8.57, S9.77.

[0142] In the next step, to a solution of 35 (50 mg, 0.133 mmol) in dry DCM (1 mL) was added N-(hexadecyl)sulfamide 38 (0.159 mmol) and BF3·OEt2 (33 μL, 0.266 mmol) under Ar atmosphere at 0 °C. The mixture was stirred for 16 h. After complete formation of the product (TLC), Et3N (0.15 mL) was added and the mixture was stirred for 10 min and concentrated. The resulting residue was purified by column chromatography (eluent 1:2 EtOAc-cyclohexane) to give 13. Yield: 62 mg (75%). R f 0.78 (1:1 EtOAc-cyclohexane). [α] D +36.55(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.44(t,1H,J 2,3 =J 3,4 =9.5Hz,H-3),5.43(bdd,1H,J 1,2 =5.0Hz,J 1,NH =2.9Hz,H-1),5.25(d,1H,NH),5.12(t,1H,J NH,CH2 =5.9Hz,NH-CH2),5.06(dd,1H,H-2),4.93(t,1H,J 4,5 =9.4Hz,H-4),4.47(t,1H,J 6a,6b =J 5,6a =8.6Hz,H-6a),4.26(t,1H,H-6b),4.14(m,1H,H-5),2.94(m,2H,CH2N),2.09,2.04,2.02(3s,9H,CH3CO),1.53-0.85(m,33H,CH2,CH2CH3). 13 C NMR (75.5 MHz, CDCl3): δ 170.1, 169.7, 169.0 (CO ester), 156.2 (CO carbamate), 72.5 (C-4), 69.2 (C-2), 69.1 (C-3), 67.2 (C-6), 59.7 (C-1), 51.5 (C-5), 43.4 (CH2N), 31.9-14.1 (CH3CO, CH2, CH2CH3). ESIMS: m / z = 656.4 [M+Na] + Anal.calcd. for C 29 H 51 N3O 10S:C54.96,H8.11,N6.63,S5.06. Found: C55.19, H8.35, N6.54, S4.80.

[0143] [Example 14. Synthesis of compound 14] Compound 14 was obtained by treating a solution of 13 (77 mg, 0.122 mmol) in MeOH (3 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Yield: 62 mg (quantitative). f 0.6(80:10:1 DCM-MeOH-H2O). [α] D +24.15(c 1.0 in acetone). 1 H NMR(300MHz,1:1CDCl3-CD3OD):δ5.07(s,1H,NH),4.86(d,1H,J 1,2 =4.8Hz,H-1),4.23(t,1H,J 6a,6b =8.7Hz,H-6a),3.97(dd,1H,J 56b =5.8Hz,H-6b),3.57(m,1H,H-5),3.32(m,2H,H-2,H-3),3.05(t,1H,H-4),2.71(m,2H,CH2N)1.28-0.59(m,33H,CH2,CH2CH3). 13 C NMR(75.5MHz,1:1CDCl3-CD3OD):δ156.3(CO carbamate),73.2(C-4),72.5(C-2),69.1(C- 3),66.1(C-6),61.8(C-1),52.3(C-5),42.0(CH2N),31.0-12.8(CH3CO,CH2,CH2CH3). ESIMS:m / z=530.32[M+Na] + Anal.calcd. for C 23 H 45 N3O7S:C54.41,H8.93,N8.28,S6.31. Found: C54.53, H8.99, N8.02, S5.98.

[0144] [Example 15. Synthesis of compound 15] To a solution of 35 (100 mg, 0.267 mmol) in dry DCM (12 mL) was added O-octylsulfamate (0.320 mmol) and BF3·OEt2 (66 μL, 0.534 mmol) under Ar atmosphere at 0 °C. The mixture was stirred for 16 h. After complete formation of the product (TLC), Et3N (0.3 mL) was added and the mixture was stirred for 10 min and concentrated. The resulting residue was purified by column chromatography (eluent 1:2→1:1 EtOAc-cyclohexane) to give 15. Yield: 80 mg (57%). R f 0.40 (1:1 EtOAc-cyclohexane). [α] D +33.76(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.75(bs,1H,NH),5.63(d,1H,J 1,2 =5.0Hz,H-1),5.46(t,1H,J 2,3 =J 3,4 =9.9Hz,H-3),5.13(dd,1H,H-2),5.02(t,1H,J 4,5 =9.5Hz,H-4),4.47(t,1H,J 6a,6b =J 5,6a =8.5Hz,H-6a),4.30(bdd,1H,J 5,6b =6.2Hz,H-6b),4.23(m,2H,CH2O)4.13(m,1H,H-5),2.13,2.08,2.06(3s,9H,CH3CO),1.75-0.89(m,15H,CH2,CH2CH3). 13 C NMR (75.5 MHz, CDCl3): δ = 170.0, 168.8 (CO ester), 154.7 (CO carbamate), 72.5 (CHO), 72.1 (C-4), 69.1 (C-3), 68.7 (C-2), 66.2 (C-6), 60.5 (C-1), 51.3 (C-5), 31.7-14.0 (CHCO, CH, CHCH). ESIMS: m / z = 545.18 [M+Na] + Anal.calcd. for C 21 H 34 N2O 11 S:C48.27,H6.56,N5.36,S6.14. Found:C48.09,H6.43,N5.18.

[0145] [Example 16. Synthesis of compound 16] Compound 16 was obtained by treating a solution of 15 (60 mg, 0.186 mmol) in MeOH (1.8 mL) with 1 M NaOMe in MeOH (73 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Yield: 73 mg (quantitative). f 0.30(70:10:1 DCM-MeOH-H2O). [α] D +20.40(c 1.0 in MeOH). 1 H NMR(300MHz,CD3OD):δ=5.29(d,1H,J 1,2 =4.7Hz,H-1),4.50(t,1H,J 6a,6b =J 5,6a =8.7Hz,H-6a),4.30(dd,1H,J 5,6b =4.8Hz,H-6b),4.17(m,2H,CH2O),3.78(m,1H,H-5),3.57(m,2H,H-2,H-3),3.32(m,1H,H-4),1.73-0.92(m,15H,CH2,CH2CH3). 13 C NMR (75.5MHz, CD3OD): δ156.4(CO),73.7(C-4),72.8(C-2),70.6(CH2O)69.9(C-3),66.3(C-6),63.2(C-1),53.1(C-5),31.5-13.0(CH2,CH2CH3). ESIMS:m / z=419.14[M+Na] + Anal.calcd. for C 15 H 28 N2O8S:C45.44,H7.12,N7.07,S8.09. Found: C45.16, H6.99, N6.81.

[0146] [Example 17. Synthesis of compound 17] To a solution of 35 (100 mg, 0.267 mmol) in dry DCM (12 mL) was added O-dodecylsulfamate (0.320 mmol) and BF3·OEt2 (66 μL, 0.534 mmol) under Ar atmosphere at 0 °C. The mixture was stirred for 16 h. After complete formation of the product (TLC), Et3N (0.3 mL) was added and the mixture was stirred for 10 min and concentrated. The resulting residue was purified by column chromatography (eluent 1:3→1:2 EtOAc-cyclohexane) to give 17. Yield: 75 mg (50%). R f 0.43 (1:1 EtOAc-cyclohexane). [α] D +28.58(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.69(d,1H,J 1,NH =3.7Hz,NH),5.63(dd,1H,J 1,2 =5.0Hz,H-1),5.46(t,1H,J 2,3 =J 3,4 =9.8Hz,H-3),5.13(dd,1H,H-2),5.02(t,1H,J 4,5 =9.5Hz,H-4),4.47(t,1H,J 6a,6b =J 5,6a =8.5Hz,H-6a),4.30(bdd,1H,J 5,6b =6.2Hz,H-6b),4.23(m,2H,CH2O)4.13(m,1H,H-5),2.13,2.09,2.06(3s,9H,CH3CO),1.75-0.89(m,23H,CH2,CH2CH3). 13 C NMR (75.5 MHz, CDCl3): δ 170.0, 168.7 (CO ester), 154.7 (CO carbamate), 72.7 (CHO), 72.1 (C-4), 69.1 (C-3), 68.7 (C-2), 66.2 (C-6), 60.6 (C-1), 51.3 (C-5), 31.8-14.1 (CHCO, CH, CHCH). ESIMS: m / z = 601.2 [M+Na] + Anal.calcd. for C 25 H 42 N2O 11S:C51.89,H7.32,N4.48,S5.54. Found:C52.10,H7.46,N4.74.

[0147] [Example 18. Synthesis of compound 18] Compound 18 was obtained by treating a solution of 17 (60 mg, 0.103 mmol) in MeOH (3 mL) with 1 M NaOMe in MeOH (31 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Yield: 44 mg (quantitative). f 0.5(80:10:1 DCM-MeOH-H2O). [α] D +30.7(c 1.0 in MeOH). 1 H NMR(300MHz,CD3OD):δ5.29(d,1H,J 1,2 =4.7Hz,H-1),4.50(t,1H,J 6a,6b =J 5,6a =8.7Hz,H-6a),4.30(dd,1H,J 5,6b =4.8Hz,H-6b),4.17(m,2H,CH2O),3.78(m,1H,H-5),3.57(m,2H,H-2,H-3),3.32(m,1H,H-4),1.73-0.91(m,23H,CH2,CH2CH3). 13 C NMR (75.5MHz, CD3OD): δ156.3(CO),73.7(C-4),72.8(C-2),70.6(CH2O)69.9(C-3),66.3(C-6),63.2(C-1),53.1(C-5),31.6-13.0(CH2,CH2CH3). ESIMS:m / z=475.21[M+Na] + Anal.calcd. for C 19 H 36 N2O8S:C50.43,H8.02,N6.19,S7.08. Found:C50.41,H7.93,N6.06.

[0148] [Example 19. Synthesis of compound 19] To a solution of 35 (100 mg, 0.267 mmol) in dry DCM (12 mL) was added O-hexadecylsulfamate (0.320 mmol) and BF3·OEt2 (66 μL, 0.534 mmol) under Ar atmosphere at 0 °C. The mixture was stirred for 16 h. After complete formation of the product (TLC), Et3N (0.3 mL) was added and the mixture was stirred for 10 min and concentrated. The resulting residue was purified by column chromatography (eluent 1:2 EtOAc-cyclohexane) to give 19. Yield: 111 mg (65%).R f 0.70 (1:1 EtOAc-cyclohexane). [α] D +27.13(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.84(bs,1H,NH),5.55(d,1H,J 1,2 =5.0Hz,H-1),5.38(t,1H,J 2,3 =J 3,4 =9.9Hz,H-3),5.04(dd,1H,H-2),4.94(t,1H,J 4,5 =9.5Hz,H-4),4.39(t,1H,J 6a,6b =J 5,6a =8.5Hz,H-6a),4.22(bdd,1H,J 5,6b =6.2Hz,H-6b),4.14(m,2H,CH2O)4.05(m,1H,H-5),2.04,2.00,1.97(3s,9H,CH3CO),1.67-0.80(m,33H,CH2,CH2CH3). 13 C NMR (75.5 MHz, CDCl3): δ 170.0, 168.8 (CO ester), 154.7 (CO carbamate), 72.5 (CHO), 72.1 (C-4), 69.1 (C-3), 68.7 (C-2), 66.2 (C-6), 60.5 (C-1), 51.3 (C-5), 31.9-14.1 (CHCO, CH, CHCH). ESIMS: m / z = 657.3 [M+Na] + Anal.calcd. for C 29 H 50 N2O 11 S:C54.87,H7.94,N4.41,S5.05. Found: C55.11, H8.17, N4.26.

[0149] [Example 20. Synthesis of compound 20] Compound 20 was obtained by treating a solution of 19 (111 mg, 0.174 mmol) in MeOH (3 mL) with 1 M NaOMe in MeOH (31 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation, and lyophilization. Yield: 88 mg (quantitative). f 0.60(80:10:1 DCM-MeOH-H2O). [α] D +24.7(c 1.0 in MeOH). 1 H NMR(300MHz,1:1 CDCl3-CD3OD):δ=5.22(d,1H,J 1,2 =4.9Hz,H-1),4.40(t,1H,J 6a,6b =J 5,6a =8.8Hz,H-6a),4.20(dd,1H,J 5,6b =4.8Hz,H-6b),4.09(m,2H,CH2O),3.70(m,1H,H-5),3.47(m,2H,H-2,H-3),3.22(m,1H,H-4),1.64-0.79(m,33H,CH2,CH2CH3). 13 C NMR(75.5MHz,1:1 CDCl3-CD3OD): δ156.3(CO),73.7(C-4),73.0(C-2),71.1(CH2O),69.8(C-3),66.4(C-6),63.1(C-1),53.0(C-5),31.7-13.6(CH2,CH2CH3). ESIMS:m / z=531.27[M+Na] + Anal.calcd. for C 23 H 44 N2O8S:C54.31,H8.72,N5.51,S6.30. Found:C54.08,H8.43,N5.19.

[0150] [Example 21. Synthesis of compound 21] To a solution of 35 (100 mg, 0.267 mmol) in dry DCM (12 mL) was added octylsulfonamide (0.320 mmol) and BF3·OEt2 (66 μL, 0.534 mmol) under Ar atmosphere at 0 °C. The mixture was stirred for 16 h. After complete formation of the product (TLC), Et3N (0.3 mL) was added and the mixture was stirred for 10 min and concentrated. The resulting residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give the sulfonamide derivative 21. Yield: 123 mg (91%). R f 0.40 (1:1 EtOAc-cyclohexane). [α] D +41.9(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3):δ5.96(bs,1H,J NH,1 =6.1Hz,NH),5.52(bt,1H,J 1,2 =5.4Hz,H-1),5.45(t,1H,J 2,3 =J 3,4 =9.9Hz,H-3),5.01(dd,1H,H-2),4.92(t,1H,J 4,5 =9.5Hz,H-4),4.40(t,1H,J 6a,6b =J 5,6a =8.5Hz,H-6a),4.22(bdd,1H,J 5,6b =6.2Hz,H-6b),4.06(m,1H,H-5),3.14(m,2H,CH2S),2.04,2.00,1.99(3s,9H,CH3CO),1.68-0.80(m,17H,CH2,CH2CH3). 13 CNMR (75.5MHz, CDCl3): δ 170.0, 169.3 (CO ester), 154.4 (CO carbamate), 72.3 (C-4), 68.8 (C-3), 68.7 (C-2), 66.9 (C-6), 59.5 (C-1), 52.7 (CH2S), 52.0 (C-5), 31.6-14.0 (CH3CO, CH2, CH2CH3). ESIMS: m / z = 529.1 [M+Na] + Anal.calcd. for C 21 H 34 N2O 10S:C49.79,H6.77,N5.53,S6.33. Found:C50.03,H6.87,N5.37,S6.21.

[0151] [Example 22. Synthesis of compound 22] Compound 22 was obtained by treating a solution of 21 (123 mg, 0.243 mmol) in MeOH (2.4 mL) with 1 M NaOMe in MeOH (100 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Yield: 92 mg (quantitative). f 0.4(70:10:1 DCM-MeOH-H2O). [α] D +33.04(c 1.0 in MeOH). 1 H NMR(300MHz,CD3OD)δ=5.21(d,1H,J 1,2 =4.9Hz,H-1),4.42(t,1H,J 2,3 =J 3,4 =8.8Hz,H-3),4.19(dd,1H,H-2),3.73(m,1H,H-5),3.48(m,2H,J 6a,6b =J 5,6a =8.7Hz,H-6a,H-4),3.25(m,1H,H-6b),3.07(m,2H,CH2S),1.71-0.79(m,17H,CH2,CH2CH3). 13 C NMR (75.5MHz, CD3OD): δ156.6(CO),73.7(C-4),73.0(C-2),69.9(C-3),66.7(C-6),62.5(C-1),53.1(C-5),52.1(CH2S),31.5-13.5(CH2,CH2CH3). ESIMS:m / z=403.15[M+Na] + Anal.calcd. for C 15 H 28 N2O7S:C47.36,H7.42,N7.36,S8.43. Found: C47.17, H7.28, N7.15, S8.20.

[0152] [Example 23. Synthesis of compound 23] Compound 23 was obtained by coupling of the isothiocyanate derivative 39 with octylamine. Precursor 39 was prepared from 35 according to Scheme 3 by the procedure described below.

[0153] [ka]

[0154] A mixture of 35 (100 mg, 0.27 mmol) and SnCl4 (1 m in DCM) in DCM (4 mL) 、 A solution of 3H (270 μL) was stirred for 5 min, trimethylsilyl isothiocyanate (42 μL, 0.29 mmol) was added and the reaction mixture was stirred at room temperature for 60 min. A saturated aqueous solution of NaHCO3 (2×45 mL) was added and the aqueous phase was extracted with DCM (3×45 mL). The organic layer was washed with water (30 mL), dried (MgSO4), filtered and concentrated. The resulting residue was purified by column chromatography (1:1 EtOAc-cyclohexane) to give 39. Yield: 80 mg (80%). R f 0.67 (1:1 EtOAc-petroleum ether). [α] D +79.6(c 1.0 in CHCl3). 1 H NMR(500MHz,CDCl3)δ6.09(d,1H,J 1,2 =4.5Hz,H-1),5.51(t,1H,J 2,3 =J 3,4 =10.0Hz,H-3),5.02(dd,1H,H-2),4.95(t,1H,J 4,5 =10.0Hz,H-4),4.49(dd,1H,J 6a,6b =9.5Hz,J 5,6a =8.0Hz,H-6a),4.30(dd,1H,J 5,6b =8.0Hz,H-6b),4.03(dt,1H,H-5),2.17-2.09(3s,9H,MeCO). 13C NMR(125.7MHz, CDCl3)δ170.0-169.5(MeCO),154.4(CO),145.2(CS),71.8(C-4) ,70.2(C-2),69.0(C-3),66.8(C-6),63.3(C-1),52.3(C-5),20.5-20.3(MeCO). ESIMS:m / z394.9[M+Na] + Anal.Calcd for C 14 H 16 N2O8S:C45.16,H4.33,N7.52,S8.61. Found: C45.15, H4.22, N7.26, S8.33.

[0155] In the next step, to a stirred solution of isothiocyanate derivative 39 (300 mg, 0.81 mmol) in anhydrous DCM (20 mL) was added n-octylamine (133 μL, 0.81 mmol) and the reaction mixture was stirred at room temperature for 90 min. The solvent was removed under reduced pressure and the resulting residue was purified by column chromatography (1:2→2:1 EtOAc-cyclohexane) to give 23. Yield: 370 mg (92%). f 0.27 (1:1 EtOAc-cyclohexane). [α] D +64.0(c 1.0,CHCl3). 1 H NMR(500MHz,CDCl3)δ7.46(bs,1H,NH),6.43(d,1H,J NH,1 =5.0Hz,NH),5.69(t,1H,J 1,2 =5.0Hz,H-1),5.45(dd,1H,J 2,3 =10.0Hz,J 3,4 =9.0Hz,H-3),5.07(dd,1H,H-2),4.96(t,1H,J 4,5 =9.0Hz,H-4),4.54(t,1H,J 6a,6b =J 5,6a =9.0Hz,H-6a),4.39(dd,1H,J 5,6b=7.5Hz,H-6b),4.06(bq,1H,H-5),3.61-3.55(m,2H,NHCH2),2.16-2.09(3s, 9H,MeCO),1.75-1.60(m,2H,NHCH2CH2),1.40-1.22(m,10H,CH2),0.90(t,3H, 3 J H,H =7.0Hz,CH3). 13 CNMR(125.7MHz,CDCl3)δ181.9(CS),170.0-169.4(MeCO),157.1(CO),72.4(C-4),68.4(C-3),68.2(C- 2),67.5(C-6),58.4(C-1),51.8(C-5),46.9(NHCH2),31.8-22.6(CH2),20.6-20.4(MeCO),14.1(CH3). ESIMS:m / z524.0([M+Na] + ). Anal.Calcd for C 22 H 35 N3O8S:C52.68,H7.03,N8.38,S6.39. Found: C52.49, H6.80, N8.12, S6.09.

[0156] [Example 24. Synthesis of compound 24] Compound 24 was obtained from the carbodiimide derivative 40 and LiAlHSeH. Precursor 40 was prepared from compound 23 according to Scheme 4 as follows:

[0157] [ka]

[0158] To a stirred solution of α-glycosylthiourea 23 (170 mg, 0.34 mmol) in DCM-H2O (1:1, 8 mL) was added HgO (220 mg, 1.02 mmol) and the reaction mixture was stirred at room temperature for 2 h. Then DCM (20 mL) was added and the organic layer was separated, dried (MgSO4), filtered through a pad of Celite and concentrated. The resulting residue was purified by column chromatography (1:1 EtOAc-cyclohexane) to give 40. Yield: 110 mg (70%). R f0.73(1:1 EtOAc-シクロヘキサン)。[α] D +41.7(c 1.0,CHCl3)。 1 H NMR(500MHz,CDCl3)δ5.72(d,1H,J 1,2 =4.5Hz,H-1),5.53(t,1H,J 2,3 =J 3,4 =9.5Hz,H-3),4.97(dd,1H,H-2),4.92(t,1H,J 4,5 =9.5Hz,H-4),4.43(t,1H,J 6a,6b =J 5,6a =8.5Hz,H-6a),4.25(t,1H,J 5,6b =8.5Hz,H-6b),4.07(bq,1H,H-5),3.36-3.25(m,2H,NCH2),2.12-2.06(3s,9H,MeCO),1.65-1.58(m,2H,NCH2CH2),1.41-1.24(m,10H,CH2),0.90(t,3H, 3 J H,H =7.0Hz,CH3)。 13 C NMR(125.7MHz,CDCl3)δ170.1-169.5(MeCO),155.1(CO),137.0(NCN),72.4(C-4),70.9(C-2),69.3(C-3),66.7(C-6),63.0(C-1),52.0(C-5),46.4(NCH2),31.8-22.6(CH2),20.6-20.5(MeCO),14.1(CH3)。ESIMS:m / z490.0([M+Na] + )。Anal.Calcd for C 22 H 33 N3O8:C56.52,H7.11,N8.99。Found:C56.58,H7.03,N8.76。

[0159] In the subsequent step, to a solution of octylcarbodiimide 40 (90 mg, 0.19 mmol) in anhydrous THF (1 mL) under Ar atmosphere, 1N solution of dry hydrogen chloride in diethyl ether (0.2 mL) was added, and the mixture was stirred at room temperature for 4 h. Then, an ex situ prepared solution of LiAlHSeH (0.96 mmol) in anhydrous THF (9 mL) was added to the previous mixture at 0° C., and the reaction mixture was stirred for 15 min, diluted with diethyl ether (50 mL), washed with brine (10 mL), dried (MgSO4), filtered, and concentrated. The resulting residue was purified by column chromatography (1:3 EtOAc-cyclohexane) to give 24. Yield: 79 mg (76%). R f 0.38 (1:1 EtOAc-cyclohexane). [α] D +72.2(c 1.2 in DCM). 1 H NMR(300MHz,CDCl3)δ7.73(bs,1H,NH),6.80(bs,1H,NH),5.58(t,1H,J 1,2 =J 1,NH =6.0Hz,H-1),5.41(t,1H,J 2,3 =J 3,4 =9.5Hz,H-3),5.02(dd,1H,H-2),4.91(t,1H,J 4,5 =9.0Hz,H-4),4.47(t,1H,J 6a,6b =J 5,6a =9.0Hz,H-6a),4.32(dd,1H,J 5,6b =7.5Hz,H-6b),4.03(bq,1H,H-5),3.56(dt,2H, 2 J H,H =12.3Hz, 3 J H,H =7.5Hz,NHCH2),2.09-2.000(3s,9H,MeCO),1.70-1.50(m,2H,NHCH2CH2),1.35-1.10(m,10H,CH2),0.81(t,3H, 3 J H,H =7.0Hz,CH3). 13C NMR(75.5MHz,CDCl3)δ180.7(CSe),170.0-169.3(MeCO),157.2(CO),72.3(C-4),68.3(C-3),68.0(C- 2),67.7(C-6),58.6(C-1),51.9(C-5),50.0(NHCH2),31.7-22.6(CH2),20.6-20.4(MeCO),14.1(CH3). ESIMS:m / z550.28[M+H] + Anal.Calcd for C 22 H 35 N3O8Se:C48.17,H6.43,N7.66. Found: C48.04, H6.29, N7.45.

[0160] [Example 25. Synthesis of compound 25] Compound 25 was obtained by treating a solution of 24 (50 mg, 0.09 mmol) in MeOH (2 mL) with 1 M NaOMe in MeOH (50 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and purification by column chromatography (8:1 DCM-MeOH). Yield: 31 mg (82%). f 0.56 (8:1 DCM-MeOH). 1 H NMR(300MHz,(CD3)2SO)δ8.02(bt,1H,J=5.4Hz,NH),7.91(d,1H,J NH,1 =7.0Hz,NH),5.89(bs,1H,H-1),5.48(d,1H,J OH,4 = 4.7Hz,OH), 5.40(d,1H,J OH,2 =3.1Hz,OH),5.07(d,1H,J OH,3 =3.4Hz,OH),4.26(t,1H,J 6a,6b =J 5,6a =8.3Hz,H-6a),4.08(dd,1H,J 5,6b =3.0Hz,H-6b),3.50-3.29(m,5H,H-2,H-3,H-5,NHCH2),3.05(td,1H,J 3,4 =J 4,5 =9.0Hz,H-4),1.50-1.35(m,2H,CH2),1.30-1.10(m,10H,CH2),0.79(t,3H,3 J H,H =6.8Hz,CH3). 13 C NMR(75.5MHz,(CD3)2SO)δ183.8(C=Se),155.6(CO),73.4-73.3(C-4,C-3),70.3(C- 2),65.9(C-6),64.9(C-1),54.2(C-5),47.0(NHCH2),31.7-22.5(CH2),14.4(CH3). ESIMS:m / z424.27[M+H] + .

[0161] [Example 26. Synthesis of compound 26] To a stirred solution of isothiocyanate derivative 39 (372 mg, 1.00 mmol) in DCM (28 mL) was added n-dodecylamine (185 mg, 1.00 mmol) and the reaction mixture was stirred at room temperature for 15 min. The solvent was removed under reduced pressure and the resulting residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give 26. Yield: 490 mg (88%). R f 0.46 (1:1 EtOAc-cyclohexane). [α] D +65.3(c 1.1 in DCM). 1 H NMR(300MHz,CDCl3)δ7.43(bs,1H,NH),6.40(d,1H,J NH,1 = 6.0Hz,NH),5.67(t,1H,J 1,2 =6.0Hz,H-1),5.43(t,1H,J 2,3 =J 3,4 =9.5Hz,H-3),5.05(dd,1H,H-2),4.94(t,1H,J 4,5 =9.5Hz,H-4),4.52(t,1H,J 6a,6b =J 5,6a =9.0Hz,H-6a),4.36(dd,1H,J 5,6b =7.6Hz,H-6b),4.03(bq,1H,H-5),3.59-3.50(m,2H,NHCH2),2.13-2.06(3s, 9H,MeCO),1.68-1.54(m,2H,NHCH2CH2),1.36-1.18(m,18H,CH2),0.87(t,3H, 3 J H,H=7.0Hz,CH3). 13 C NMR(75.5MHz,CDCl3)δ181.9(CS),170.0-169.3(MeCO),157.1(CO),72.4(C-4),68.3(C-3),68.2(C-2 ), 67.6 (C-6), 58.4 (C-1), 51.8 (C-5), 47.0 (NHCH2), 31.9-22.7 (CH2), 20.6-20.4 (MeCO), 14.1 (CH3). ESIMS:m / z580.3[M+Na] + Anal.Calcd for C 26 H 43 N3O8S:C55.99,H7.77,N7.53,S5.75. Found: C55.67, H7.55, N7.21, S5.41.

[0162] [Example 27. Synthesis of compound 27] Compound 27 was obtained by treating a solution of 26 (27 mg, 0.05 mmol) in MeOH (0.7 mL) with 1 M NaOMe in MeOH (20 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Column chromatography (6:1→4:1 EtOAc-MeOH). Yield: 19.4 mg (94%). R f 0.56(4:1 EtOAc-MeOH). [α] D -21.3 (c 0.9 in DMSO). 1 H NMR(300MHz,DMSO-d6)δ8.14-7.99(m,2H,NH),5.99(t,1H,J 1,2 =J 1,NH =6.0Hz,H-1),5.60(d,1H,J OH,4 = 4.5Hz,OH),5.34(d,1H,J OH,2 = 4.5Hz,OH),5.17(d,1H,J OH,3 = 4.2Hz,OH), 4.29(t,1H,J 6a,6b =J 5,6a =8.5Hz,H-6a),4.16(dd,1H,J 5,6b =2.7Hz,H-6b),3.56-3.28(m,5H,H-2,H-3,H-5,NHCH2),3.09(td,1H,J 3,4 =J4,5 =9.0Hz,H-4),1.60-1.20(m,20H,CH2),0.86(t,3H, 3 J H,H =6.5Hz,CH3). 13 C NMR(75.5MHz,DMSO-d6)v184.1(C=S),155.5(CO),73.5(C-4),73.2(C-3),70.5(C- 2),65.6(C-6),63.3(C-1),54.1(C-5),44.3(NHCH2),31.8-22.5(CH2),14.4(CH3). ESIMS:m / z454.4[M+Na] + Anal.Calcd for C 20 H 37 N3O5S:C55.66,H8.64,N9.74,S7.43. Found: C55.31, H8.29, N9.40, S7.06.

[0163] [Example 28. Synthesis of compound 28] Compound 28 was obtained from carbodiimide derivative 41 and LiAlHSeH. Precursor 41 was prepared from compound 26 according to Scheme 5 as follows:

[0164] [ka]

[0165] To a stirred solution of α-glycosylthiourea 26 (490 mg, 0.88 mmol) in DCM-H2O (1:1, 21 mL) was added HgO (572 mg, 2.64 mmol) and the reaction mixture was stirred at room temperature for 1 h. DCM (20 mL) was then added and the organic layer was separated, dried (MgSO4), filtered through a pad of Celite and concentrated. The resulting residue was purified by column chromatography (1:1 EtOAc-cyclohexane) to give 41. Yield: 423 mg (92%). R f 0.33 (1:1 EtOAc-cyclohexane). [α] D +52.0(c 1.0 in DCM). 1 H NMR(300MHz,CDCl3)δ5.63(d,1H,J1,2 =4.2Hz,H-1),5.43(t,1H,J 2,3 =J 3,4 =10.0Hz,H-3),4.92(dd,1H,H-2),4.88(t,1H,J 4,5 =10.0Hz,H-4),4.34(dd,1H,J 6a,6b =9.0Hz,J 5,6a =8.1Hz,H-6a),4.18(t,1H,J 5,6b =9.0Hz,H-6b),4.09-3.92(m,1H,H-5),3.30-3.13(m,2H,NCH2)2.03-1.97(3s,9H,MeCO),1.59-1.46(m,2H,NCH2CH2),1.30-1.15(m,18H,CH2),0.81(t,3H, 3 J H,H =7.0Hz,CH3)。 13 C NMR(75.5MHz,CDCl3)δ169.9-169.3(MeCO),154.9(CO),136.8(NCN),72.1(C-4),70.6(C-2),69.1(C-3),66.5(C-6),62.8(C-1),51.8(C-5),46.2(NCH2),31.7-22.5(CH2),20.3(MeCO),13.9(CH3)。ESIMS:m / z546.4[M+Na] + 。HRFABMS Calcd for C 26 H 41 N3O8SNa[M+Na] + 546.2786,found546.2765。

[0166] In the subsequent step, to a solution of α-dodecylcarbodiimide 41 (96 mg, 0.18 mmol) in anhydrous THF (1 mL) under Ar atmosphere, 1N HCl in Et2O (0.18 mL) was added and the mixture was stirred at room temperature for 4 h. Subsequently, an in situ prepared solution of LiAlHSeH (0.96 mmol) in anhydrous THF (9 mL) was added to the aforementioned mixture at 0 °C and the resulting reaction was stirred for 90 min, diluted with diethyl ether (50 mL), washed with brine (10 mL), dried (MgSO4), filtered and concentrated. The resulting residue was purified by column chromatography (1:3 EtOAc-cyclohexane) to give 28. Yield: 51 mg (47%). R f 0.47 (1:1 EtOAc-cyclohexane). [α] D +55.0(c 1.3 in DCM). 1 H NMR(300MHz,CDCl3)δ7.81(bs,1H,NH),6.74(d,1H,J NH,1 = 6.0Hz,NH),5.61(t,1H,J 1,2 =6.0Hz,H-1),5.43(dd,1H,J 2,3 =10.0Hz,J 3,4 =9.0Hz,H-3),5.04(dd,1H,H-2),4.92(t,1H,J 4,5 =9.0Hz,H-4),4.53(t,1H,J 6a,6b =J 5,6a =9.3Hz,H-6a),4.38(dd,1H,J 5,6b =7.5Hz,H-6b),4.03(bq,1H,H-5),3.63(dt,2H, 2 J H,H =12.3Hz, 3 J H,H =7.5Hz,NHCH2),2.16-2.07(3s,9H,MeCO),1.70-1.55(m,2H,NHCH2CH2),1.35-1.20(m,18H,CH2),0.88(t,3H, 3 J H,H =7.0Hz,CH3). 13C NMR(75.5MHz,CDCl3)δ180.7(CSe),169.9-169.2(MeCO),157.2(CO),72.4(C-4),68.2(C-3),68.0(C- 2),67.7(C-6),58.5(C-1),51.9(C-5),50.1(NHCH2),31.9-22.7(CH2),20.6-20.5(MeCO),14.1(CH3). 77 Se NMR (95.4MHz, CDCl3, 323K) δ240.4. ESIMS:m / z628.2[M+Na] + Anal.Calcd for C 26 H 43 N3O8Se:C51.65,H7.17,N6.95. Found:C51.40,H6.89,N6.63.

[0167] [Example 29. Synthesis of compound 29] Compound 29 was obtained by treating a solution of 28 (20 mg, 0.03 mmol) in MeOH (0.7 mL) with 1 M NaOMe in MeOH (20 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Column chromatography (6:1 DCM-MeOH). Yield: 13 mg (82%). R f 0.67(9:1 DCM-MeOH). [α] D -11.2 (c 1.0 in DMSO). 1 H NMR(300MHz,DMSO-d6)δ8.03(t,1H,J=4.7Hz,NH),7.94(d,1H,J NH,1 =7.2Hz,NH),5.95(bs,1H,H-1),5.57(d,1H,J OH,4 =5.0Hz,OH),5.50(d,1H,J OH,2 =3.3Hz,OH),5.16(d,1H,J OH,3 =3.9Hz,OH),4.32(t,1H,J 6a,6b =J 5,6a =8.1Hz,H-6a),4.14(dd,1H,J 5,6b =3.0Hz,H-6b),3.55-3.31(m,5H,H-2,H-3,H-5,NHCH2),3.12(td,1H,J 3,4 =J4,5 =9.0Hz,H-4),1.55-1.41(m,2H,CH2),1.35-1.15(m,18H,CH2),0.85(t,3H, 3 J H,H =7.0Hz,CH3). 13 C NMR(75.5MHz,DMSO-d6)δ183.3(C=Se),155.1(CO),72.9-72.8(C-4,C-3),69.8(C- 2),65.4(C-6),64.4(C-1),53.7(C-5),46.5(NHCH2),31.3-22.1(CH2),13.9(CH3). ESIMS:m / z478.1[MH] - Anal.Calcd for C 20 H 37 N3O5Se:C50.20,H7.79,N8.78. Found: C49.91, H7.55, N8.66.

[0168] [Example 30. Synthesis of compound 30] To a stirred solution of isothiocyanate derivative 39 (210 mg, 0.56 mmol) in DCM (14 mL) was added hexadecylamine (136 mg, 0.56 mmol) and the reaction mixture was stirred at room temperature for 60 min. The solvent was removed under reduced pressure and the resulting residue was purified by column chromatography (1:2→2:1 EtOAc-cyclohexane) to give 30. Yield: 265 mg (77%). R f 0.47 (1:1 EtOAc-cyclohexane). [α] D +41.4(c 1.2,CH2Cl2). 1 H NMR(300MHz,CDCl3)δ7.36(bs,1H,NH),6.35(d,1H,J NH,1 =6.2Hz,NH),5.61(t,1H,J 1,2 =5.9Hz,H-1),5.38(dd,1H,J 2,3 =10.0Hz,J 3,4 =9.2Hz,H-3),5.00(dd,1H,H-2),4.89(t,1H,J 4,5 =9.2Hz,H-4),4.56(t,1H,J 6a,6b =J 5,6a=9.0Hz,H-6a),4.30(dd,1H,J 5,6b =7.6Hz,H-6b),3.98(bq,1H,H-5),3.55-3.43(m,2H,NHCH2),2.07-2.00(3s, 9H,MeCO),1.62-1.48(m,2H,NHCH2CH2),1.32-1.09(m,26H,CH2),0.81(t,3H, 3 J H,H =6.5Hz,CH3). 13 C NMR(75.5MHz,CDCl3)δ181.9(CS),170.0-169.3(MeCO),157.1(CO),72.4(C-4),68.3(C-3),68.2(C-2 ), 67.6 (C-6), 58.4 (C-1), 51.8 (C-5), 46.9 (NHCH2), 31.9-22.7 (CH2), 20.5-20.4 (MeCO), 14.1 (CH3). ESIMS:m / z614.54([M+H] + ).Anal.Calcd for C 30 H 51 N3O8S:C58.70,H8.38,N6.85,S5.22. Found: C58.81, H8.47, N6.75, S5.03.

[0169] [Example 31. Synthesis of compound 31] Compound 31 was obtained from carbodiimide derivative 42 and LiAlHSeH. Precursor 42 was prepared from compound 30 according to Scheme 6 as follows:

[0170] [ka]

[0171] To a stirred solution of 30 (330 mg, 0.53 mmol) in DCM-H2O (1:1, 14 mL) was added HgO (350 mg, 1.61 mmol) and the reaction mixture was stirred at room temperature for 2 h. Then DCM (20 mL) was added and the organic layer was separated, dried (MgSO4), filtered through a pad of Celite and concentrated. The resulting residue was purified by column chromatography (1:3 EtOAc-cyclohexane) to give 42. Yield: 260 mg (83%). R f 0.73 (1:1 EtOAc-cyclohexane). [α] D +37.0(c 1.2,DCM). 1 H NMR(300MHz,CDCl3)δ5.62(d,1H,J 1,2 =4.4Hz,H-1),5.44(t,1H,J 2,3 =J 3,4 =9.8Hz,H-3),4.88(dd,1H,H-2),4.84(t,1H,J 4,5 =9.5Hz,H-4),4.33(t,1H,J 6a,6b =J 5,6a =8.7Hz,H-6a),4.16(t,1H,J 5,6b =8.5Hz,H-6b),4.00(bq,1H,H-5),3.30-3.14(m,2H,NCH2),2.03-1.97(3s, 9H,MeCO),1.57-1.45(m,2H,NCH2CH2),1.34-1.10(m,26H,CH2),0.81(t,3H, 3 J H,H =7.0Hz,CH3). 13 C NMR(75.5MHz,CDCl3)δ170.1-169.5(MeCO),155.1(CO),137.0(NCN),72.4(C-4),70.9(C-2),69.3 (C-3),66.7(C-6),63.0(C-1),52.0(C-5),46.4(NCH2),31.9-22.7(CH2),20.5(MeCO),14.1(CH3). ESIMS:m / z602.48([M+Na] + ). In the subsequent step, to a solution of α-hexadecylcarbodiimide 42 (180 mg, 0.31 mmol) in anhydrous THF (1.6 mL) under Ar atmosphere, 1N solution of dry hydrogen chloride in diethyl ether (319 μL) was added and the mixture was stirred at room temperature for 4 h. Then, an in situ prepared solution of LiAlHSeH (1.55 mmol) in anhydrous THF (15 mL) was added to the aforementioned mixture at 0° C., and the resulting reaction mixture was stirred for 15 min, diluted with diethyl ether (50 mL), washed with brine (10 mL), dried (MgSO4), filtered and concentrated. The resulting residue was purified by column chromatography (1:2→1:1 EtOAc-cyclohexane) to give 31. Yield: 100 mg (49%). R f 0.47 (1:1 EtOAc-cyclohexane). [α] D +54.4(c 1.2 in DCM). 1 H NMR(300MHz,CDCl3)δ7.73(bs,1H,NH),6.74(d,J 1,NH =6.1Hz 1H,NH),5.56(t,1H,J 1,2 =6.1Hz,H-1),5.38(t,1H,J 2,3 =J 3,4 =10.0Hz,H-3),5.00(dd,1H,H-2),4.88(t,1H,J 4,5 =9.0Hz,H-4),4.46(t,1H,J 6a,6b =J 5,6a =9.0Hz,H-6a),4.31(dd,1H,J 5,6b =7.6Hz,H-6b),3.97(bq,1H,H-5),3.56(dt,2H, 2 J H,H =12.3Hz, 3 J H,H =7.4Hz,NHCH2),2.09-2.00(3s,9H,MeCO),1.64-1.51(m,2H,NHCH2CH2),1.33-1.11(m,26H,CH2),0.81(t,3H, 3 J H,H =7.0Hz,CH3). 13C NMR(75.5MHz,CDCl3)δ180.8(C=Se),170.0-169.2(MeCO),157.2(CO),72.4(C-4),68.3(C-3),68.0(C- 2),67.7(C-6),58.6(C-1),51.9(C-5),50.1(NHCH2),31.9-22.7(CH2),20.6-20.4(MeCO),14.1(CH3). ESIMS:m / z662.41[M+H] + .

[0172] [Example 32. Synthesis of compound 32] Compound 32 was obtained by treating a solution of 31 (73 mg, 0.11 mmol) in MeOH (0.7 mL) with 1 M NaOMe in MeOH (20 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation and lyophilization. Column chromatography (8:1→7:1 DCM-MeOH). Yield: 48 mg (81%). R f 0.47(8:1 DCM-MeOH). [α] D -11.2 (c 1.0 in DMSO). 1 H NMR(300MHz,(CD3)2SO)δ8.14(bt,1H,J=5.0Hz,NH),8.03(d,1H,J NH,1 =7.1Hz,NH),5.97(bs,1H,H-1),5.56(d,1H,J OH,4 = 4.7Hz,OH), 5.46(d,1H,J OH,2 =3.8Hz,OH),5.15(d,1H,J OH,3 =3.9Hz,OH),4.33(t,1H,J 6a,6b =J 5,6a =8.3Hz,H-6a),4.15(dd,1H,J 5,6b =3.0Hz,H-6b),3.55-3.33(m,5H,H-2,H-3,H-5,NHCH2),3.12(td,1H,J 3,4 =J 4,5 =8.6Hz,H-4),1.55-1.41(m,2H,NHCH2CH2),1.33-1.18(m,26H,CH2),0.86(t,3H, 3 J H,H =6.9Hz,CH3). 13C NMR(75.5MHz,(CD3)2SO)δ183.8(C=Se),155.6(CO),73.4-73.3(C-4,C-3),70.3(C- 2),65.9(C-6),64.9(C-1),54.2(C-5),47.0(NHCH2),31.7-22.5(CH2),14.4(CH3). ESIMS:m / z536.38[M+H] + .

[0173] [Example 33. Synthesis of compound 33] To a solution of isothiocyanate 39 (100 mg, 0.27 mmol) in toluene (3 mL), dodecanol (90 μL) was added and the reaction mixture was stirred under reflux at 110° C. overnight. The solvent was evaporated and the residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give 33. Yield: 90 mg (60%). f 0.40 (1:1 EtOAc-cyclohexane). [α] D +18.09(c 1.0 in DCM). 1 H NMR(500MHz,CDCl3):5.32(t,1H,J 1,2 =6.0Hz,H-1),5.03(m,1H,H-3),4.95(t,1H,J 4,5 =9.8Hz,H-4),4.34(m,3H,CH2O),4.19(dd,1H,J 6a,6b =9.2Hz J 5,6b =4.4Hz,H-6b),3.87(m,1H,H-5),2.09,2.00,1.98(3s,9H,COCH3),1.67-1.19(m,20H,CH2),0.81(t,3H, 3 J H,H =7.0Hz,CH3). 13 C NMR (75.5 MHz, CDCl3): δ 191.4 (CS), 169.9, 168.9, 168.8 (CO ester), 154.3 (CO carbamate), 73.3 (C-3), 71.7 (C-4), 69.5 (C-1), 68.0 (C-2), 65.4 (C-6), 51.5 (C-5), 47.0 (CHO), 31.9-14.1 (CH 2, CH3). HRMS(ESI) calcd for [C 26 H42 O9N2SNa] + 581.2503;found 581.2496.

[0174] [Example 34. Synthesis of compound 34] Compound 34 was obtained by treating a solution of 33 (90 mg, 0.162 mmol) in MeOH (2 mL) with 1 M NaOMe in MeOH (48 μL), followed by neutralization with Amberlite® IR120 hydrogen form, filtration, evaporation, and purification by column chromatography (100:10:1 DCM-MeOH-H2O). Yield: 69 mg (quantitative). f 0.70(100:10:1 DCM-MeOH-H2O). [α] D +10.21(c 1.0 in MeOH). 1 H NMR(500MHz,323K CDCl3):4.51(m,1H,H-1),4.45(m,2H,CH2O),4.33(dd,1H,J 6a,6b =9.1Hz,J 5,6b =3.6Hz,H-6b),3.68(m,1H,H-5),3.65(m,2H,H-4,H-2),3.33(t,1H,J 3,4 =9.3Hz,H-3),1.79-1.33(m,20H,CH2),0.93(t,3H, 3 J H,H =7.0Hz,CH3). 13 C NMR(125.7MHz,323K,CDCl3):δ192.2(CS),156.4(CO carbamate),73.3(C-3),73.0(C-4) ,69.8(C-1),68.0(C-2),65.8(C-6),53.7(C-5),47.0(CH2O),31.5-12.9(CH2,CH3). ESIMS:m / z=433.37[M+H] + .

[0175] Example 35. Stability of glycolipid mimetics of the present invention against the action of glucosidases. Representative compounds 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 32, and 34 were examined for their glycosidic bond stability when incubated with human fibroblast lysate for 4 h. To this end, cells were scraped into ice-cold water (10 6 cells mL -1 ), and dissolved by sonication. Insoluble material was removed by centrifugation at 15,000 rpm for 5 min, and protein concentration was measured using a Protein Assay Rapid Kit (WAKO, Tokyo, Japan). 10 μL of the lysate dissolved in 0.1% Triton X-100 in distilled water was incubated at 37°C with 20 μL of compound solution (200 μM) dissolved in 0.1 M citrate buffer, pH 4.5. In control experiments, the activity of various lysosomal glycosidases was confirmed using fluorescent substrates. The substrates were 4-methylumbelliferone (4-MU)-linked β-D-glucopyranoside (for GCase), α-D-glucopyranoside (for α-glucosidase), α-D-galactopyranoside (for α-galase), and β-D-galactopyranoside (for β-galactosidase). The liberated 4-methylumbelliferone was measured in blackwell plates using a Perkin Elmer Luminescence Spectrometer (excitation wavelength: 340 nm, emission wavelength: 460 nm).No traces of free polysubstituted 2-oxa-3-oxoindolizidines resulting from hydrolysis of the glycolipid mimics were detected by gas chromatography after trimethylsilylation, confirming the stability of the compounds against the action of glycosidases.

[0176] [Example 36. Suppression of LPS-induced inflammation (spleen cells in vitro)] Spleen cells were treated with the compounds of the present invention and LPS simultaneously to evaluate the inhibitory function of the compounds against LPS-induced inflammation. Selected results are shown in Figure 1. Several compounds, especially compounds 4, 6, 14, 27, and 29, showed significant inhibitory function against inflammation.

[0177] [Example 37. Suppression of LPS-induced inflammation (BMDM in vitro)] Since macrophages are the primary responders to LPS-induced inflammation, we assessed the ability of selected compounds to suppress LPS-induced inflammation in bone marrow-derived macrophages (BMDMs). The data shown in Figure 2 indicate that compounds 4 and 14 efficiently suppress LPS-induced inflammation.

[0178] [Example 38. Suppression of LPS-induced inflammation in vivo] To investigate the anti-inflammatory function in vivo, the ability of compound 29 to suppress LPS-induced inflammation in B6 mice was evaluated. In Figure 3, the levels of TNFα in serum were shown to be significantly suppressed when injected twice within 30 min after LPS treatment, confirming that compound 29 efficiently suppressed LPS-induced inflammation.

[0179] [Example 39. ERK and p38 of the MAPK family, as well as STAT3, are inhibited by the novel compound.] Using multiplex bead arrays, we investigated how the novel compounds exert their inhibitory effects in terms of signal transduction. As a representative example, in Figure 4, we found that the phosphorylation of ERK and p38 of the MAPK family, but not JNK, was significantly reduced by compounds 4 and 14 compared to LPS treatment alone. Therefore, the novel compounds may exert their anti-inflammatory function by suppressing the phosphorylation of ERK and p38. It was also confirmed that compound 14 significantly reduced the phosphorylation of STAT3.

[0180] [Example 40. Suppression of αGalCer-induced inflammation (spleen cells in vitro)] Spleen cells were treated simultaneously with the compounds of the present invention and αGalCer to evaluate their ability to suppress αGalCer-induced inflammation. Selected results are shown in Figure 5. All of the compounds shown in Figure 5 exhibited significant anti-inflammatory function against αGalCer-induced inflammation.

[0181] [Example 41. Immunostimulatory function of compounds (spleen cells in vitro)] The immune stimulatory function of the compounds was evaluated by treating spleen cells with only the compounds of the present invention and measuring their ability to promote the secretion of IFN-γ and IL-4. As a representative example, in Figure 6, compound 29 was effective in promoting the production of IFNγ but not in promoting the production of IL-4, confirming that compound 29 has a Th1 bias.

[0182] [Example 42. Suppression of OVA-induced airway hyperresponsiveness (AHR) and inflammation in vivo] Using a Th2 OVA-induced AHR mouse model, the Th2 inflammation suppression ability of selected compounds 14 and 29 was evaluated. The results showed that compound 14 could suppress the development of AHR (Figure 7). Furthermore, it was observed that compound 29 could significantly suppress the increase of IL-13 and IL-4, which are the main inducers of AHR, in BALF (Figure 8) and pulmonary IL-13 (protein in Figure 9 and mRNA in Figure 10).

[0183] [Example 43. Evaluation of the adjuvant function of the compound in vivo] In addition to evaluating the ability of the novel compounds to suppress inflammation, their ability to act as adjuvants, i.e., promote desirable immunological trends in vaccine development, was also examined. Selected compound 29 was measured for its in vivo adjuvant ability to induce IFNγ and IL-4 in B6 mice (Figure 11). Compound 29 showed significant ability to induce both IFNγ and IL-4 2 hours after injection, with significant detectable levels of IFNγ even 18 hours after injection. This result strongly supports the use of the compounds of the present invention as adjuvants in vaccine formulations. [Brief description of the drawings]

[0184] [Figure 1] Inhibition of LPS-induced inflammation (in vitro spleen cells) Spleen cells were treated simultaneously with the compound of the present invention and LPS to evaluate the inhibitory function of the compound against LPS-induced inflammation, and some compounds showed significant inhibitory function. [Diagram 2] Compounds 4 and 14 were evaluated for their ability to suppress LPS-induced inflammation in bone marrow derived macrophages (BMDM in vitro), and both showed significant suppression of IL-6 at 50 μM and TNFα at 10 μM and 50 μM. [Diagram 3] Figure 1 shows the suppression of LPS-induced inflammation in vivo. The ability of compound 29 to suppress LPS-induced inflammation in B6 mice in vivo was evaluated as shown in the scheme. Compound 29 was shown to significantly suppress LPS-induced serum TNFα when injected twice within a 30-minute period after LPS treatment. [Figure 4] This shows that the MAPK family ERK and p38, as well as STAT3, are inhibited by novel compounds. Using multiplex bead arrays, we investigated how the novel compounds exert their inhibitory effects from the perspective of signal transduction, using compounds 4 and 14, which are representative compounds of the present invention. Compared with LPS treatment alone, compounds 4 and 14 significantly reduced the phosphorylation of mitogen-activated protein kinases (MAPKs), ERK and p38, but not JNK, 30 minutes after treatment. A significant reduction in the phosphorylation of STAT3 by compound 14 was also observed 30 minutes after treatment. [Diagram 5] Inhibition of αGalCer-induced inflammation (in vitro spleen cells) Spleen cells were treated simultaneously with the compound of the present invention and αGalCer to evaluate the inhibitory function of the compound against αGalCer-induced inflammation, and some compounds showed significant inhibitory function. [Figure 6] Show the immune stimulating function of compound (in vitro spleen cells). Spleen cells are treated with the compounds of the present invention alone to evaluate the immune stimulating function of compound. Only compound 29 induces significant IFNγ secretion, and none of the compounds can induce significant IL-4 secretion. [Figure 7]Inhibition of ovalbumin (OVA)-induced airway hyperresponsiveness (AHR) in vivo. The in vivo Th2 inflammation suppression ability of selected compounds 14 and 29 was evaluated using an OVA-induced AHR mouse model. Compound 29 was confirmed to significantly suppress AHR. [Figure 8] Inhibition of OVA-induced airway inflammation (BALF) in vivo. Bronchoalveolar lavage fluid (BALF) from mice in OVA-induced AHR experiments was examined for their IL-13 and IL-4 levels. Compound 29 was shown to significantly inhibit both IL-13 and IL-4 levels. [Figure 9] Inhibition of OVA-induced airway inflammation in vivo (lung protein). Lungs of mice from OVA-induced AHR experiments were examined for IL-13 and IL-4 protein levels. Only compound 29 showed significant inhibition of IL-13, and no significant inhibition of IL-4 was observed in any of the compounds tested. [Figure 10] Inhibition of OVA-induced airway inflammation in vivo (lung mRNA). Lungs from mice in OVA-induced AHR experiments were examined for their IL-13 and IL-4 mRNA levels. Both compounds 14 and 29 significantly inhibited IL-13 and IL-4 mRNA levels. [Figure 11] The adjuvant function of the compound in vivo is shown. The adjuvant function of the selected compound 29 in vivo was evaluated by measuring the serum levels of IFNγ and IL-4 induced after injection in B6 mice. Compound 29 showed significant ability to induce both IFNγ and IL-4 2 hours after injection, and also showed significant detectable levels of IFNγ 18 hours after injection.

Claims

1. Compounds of Formula I: [Formula 1] where R 1 are each independently -H, -CH 2 Ph(Bn), -COPh(Bz), -CO-C 1 -C 12 Alkyl, C 1 -C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2 is replaced by; R 2 is -OH, -N(R 3 ) 2 , -N 3 , C 1 -C 4 alkyl, or halogen; R 3 are each independently H or C 1 -C 4 is alkyl; X is -C(=S)-OY, -C(=Se)-NHY, -SO 2 -NYY', -SO 2 -OY, or -P(=O)(OY) 2 and Y is one or more groups R 4 -C optionally substituted with 1 -C 25 is alkyl; Y′ is H or one or more groups R 4 -C optionally substituted with 1 -C 25 is alkyl; R 4 is -OH, OBn, C 1 -C 12 Alkyl, —O—C 1 -C 12 Alkyl, -S-C 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , -C(=O)-C 1 -C 12 Alkyl, or Cy 1 and Cy 1 is a 5- to 14-membered ring which may be saturated, partially unsaturated, or aromatic, and optionally contains a total of 1 to 4 identical or different heteroatoms selected from N, O, S, or P; Cy 1 can be optionally fused to a 5- or 6-membered carbocyclic or heterocyclic ring, which may be saturated, partially unsaturated, or aromatic; Cy 1 is optionally phenyl, halogen, C 1 -C 4 Alkyl, halo-C 1 -C 4 Alkyl, —O—C 1 -C 4 Alkyl, -OCOO-C 1 -C 4 Alkyl, —CO—C 1 -C 4 Alkyl, S-C 1 -C 4 Alkyl, or N 3 -C 1 -C 4 and substituted with one or more groups selected from alkyl.

2. R 1 are each independently -H, -Bn, -Bz, or -CO-C 1 -C 4 Alkyl, and -C 1 -C 4 alkyl; R 1 each independently optionally represents one or more groups R 2 2. The compound of formula I according to claim 1, substituted by:

3. X is -C(=S)-OY, -C(=Se)-NHY, -SO 2 -NYY', -SO 2 -OY, or -P(=O)(OY) 2 3. A compound of formula I according to claim 1 or 2, selected from:

4. Y is optionally one or more groups R 4 substituted with -C 2 -C 18 4. A compound of formula I according to any one of claims 1 to 3, which is alkyl.

5. Y′ is H or one or more groups R 4 -C optionally substituted with 2 -C 18 5. A compound of formula I according to any one of claims 1 to 4, which is alkyl.

6. A compound of formula I according to claim 1 selected from: [chemical 2] [ka] [ka] [ka]

7. A pharmaceutical composition comprising at least one compound of formula I or mixtures or combinations thereof.

8. A compound of formula I according to any one of claims 1 to 6 or a pharmaceutical composition thereof for use as a medicament.

9. A compound of formula I as defined in any one of claims 1 to 6 or a pharmaceutical composition thereof for use in the treatment and / or prevention of immune disorders.

10. The compound of formula I or a pharmaceutical composition thereof for use according to claim 9, wherein the immune disease is selected from acute inflammation, chronic disease allergy, cancer chemotherapy, infectious disease, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), immune-mediated hepatitis, autoimmune diseases, transplant rejection pathologies, inflammatory bowel disease, atherosclerosis and airway hyperresponsiveness.

11. A compound of formula I' or a pharmaceutical composition thereof for use in the treatment and / or prevention of immune disorders: [C3] where R 1 are each independently -H, -CH 2 Ph (Bn), -COPh (Bz), -CO-C 1 -C 12 Alkyl, C 1 -C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2 is replaced by; R 2 is -OH, -N(R 3 ) 2 , -N 3 , C 1 -C 4 alkyl, or halogen; R 3 Each independently represents H or C 1 -C 4 is alkyl; X is -C(=S)-OY, -C(=S)-NYY', -C(=O)-NYY', C(=Se)-NHY, -C(=NY)-NHY', -SO 2 -Y, -SO 2 -NYY', -SO 2 -OY, or -P(=O)(OY) 2 and Y is one or more groups R 4 -C optionally substituted with 1 -C 25 is alkyl; Y′ is H or one or more groups R 4 -C optionally substituted with 1 -C 25 is alkyl; R 4 is -OH, OBn, C 1 -C 12 Alkyl, —O—C 1 -C 12 Alkyl, -S-C 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , -C(=O)-C 1 -C 12Alkyl, or Cy 1 and Cy 1 is a 5- to 14-membered ring which may be saturated, partially unsaturated, or aromatic, and optionally contains a total of 1 to 4 identical or different heteroatoms selected from N, O, S, or P; Cy 1 can be optionally fused to a 5- or 6-membered carbocyclic or heterocyclic ring, which may be saturated, partially unsaturated, or aromatic; Cy 1 is optionally phenyl, halogen, C 1 -C 4 Alkyl, halo-C 1 -C 4 Alkyl, —O—C 1 -C 4 Alkyl, -OCOO-C 1 -C 4 Alkyl, —CO—C 1 -C 4 Alkyl, S-C 1 -C 4 Alkyl, or N 3 -C 1 -C 4 substituted with one or more groups selected from alkyl, Here, the immune disease is selected from acute inflammation, chronic disease allergy, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), immune-mediated hepatitis, autoimmune disease, transplant rejection pathology, inflammatory bowel disease, atherosclerosis and airway hyperresponsiveness.

12. A compound of formula I' or a pharmaceutical composition thereof for use according to claim 11 selected from: [C4] [ka] [ka] [ka] [ka]

13. The compound of formula I' or a pharmaceutical composition thereof for use according to claim 11 or 12, wherein said airway hyperresponsiveness is selected from asthma and allergic rhinitis.

14. 14. A vaccine comprising an effective amount of a compound of formula I' according to any one of claims 11 to 13 or a pharmaceutical salt thereof and a vaccine agent.